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Introduction:  There is a global rise in diverticular disease (DD) in Westernized countries 
although the prevalence in South Africa (SA) is unknown.  This has a significant effect, not only 
on the quality of life but also economically as the requirement for surgical interventions and 
hospital admissions have increased, putting additional pressure on healthcare systems. Dietary 
approaches to the treatment of DD differ and are contradictory.  The traditional restrictive low 
fiber diet approach recommends the avoidance of insoluble fiber including nuts, seeds, popcorn 
and corn while the International Current Consensus Guidelines (ICCG) from a number of 
countries such as Italy, Poland, Denmark, America, Great Britain, advocate a liberal unrestricted 
high fiber diet (HFD).  Although the ICCG have concluded that the consumption of nuts, seeds 
and popcorn does not appear to exacerbate DD symptoms and complications, there has been 
anecdotal evidence that their inclusion may worsen symptoms and provoke attacks in some 
patients suffering with symptomatic uncomplicated DD (SUDD).  There are also conflicting 
views as to whether fiber supplementation is necessary in SUDD.  
 
Aim:  The aim was to determine dietary treatment methods used by registered dietitians (RDs) 
practicing in SA when treating SUDD and to determine their beliefs regarding the ICCG for 
SUDD, trigger foods and the use of fiber, prebiotic and probiotic supplements. 
 
Methods:  Snowball sampling was used in this quantitative descriptive study to identify 155 RDs 
in SA who treated SUDD.  The RDs completed a closed and open-ended self-administered 
questionnaire.   
 
Results: Diverticular disease was treated by 75% of dietitians in the private sector compared to 
25% in the government sector.  A third of the dietitians treated less than five patients per year and 
a third treated two or more patients per month.  Their approach to treatment was not significantly 
different.  A significant portion (77%) disagreed with the ICCG and 79% identified foods 
(including seeds, nuts, pips, wheat, popcorn and fruits), which they believed triggered symptoms.  
None supplemented with bran and only 1.3% recommended insoluble fiber. Supplementation 




probiotics.  The main probiotic species prescribed were Lactobacillus acidophilus, 
Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium bifidum, Lactobacillus casei, 
Lactobacillus rhamnosous, Lactobacillus plantarum and Streptococcus thermophiles.  Only 7%, 
however, prescribed an evidence based strain.  Many RDs (74%) felt that patients responded well 
to their treatment with significant improvement in symptoms and had a decreased relapse rate.  
 
Conclusion:  The majority of dietitians practicing in SA do not support the ICCG advocating a 
liberal, unrestricted HFD as the appropriate dietary approach for the treatment of SUDD.  An 
individual treatment approach for each patient was reported throughout the study.  Practice 
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1. INTRODUCTION, THE PROBLEM AND ITS SETTING 
 
1.1 IMPORTANCE OF THE STUDY 
 
The incidence of DD has risen in industrialized countries (Tursi 2010).  Diverticular disease 
results in a significant loss of quality of life (abdominal pain, bloating, constipation, diarrhoea, 
nausea, flatulence) and in severe cases, mortality (Commane, Arasaradnam, Mills, Mathers & 
Bradburn 2009; Tursi 2010).  Over the last 10 to 20 years, there has been an increase in hospital 
admissions, (Tursi 2010; Cuomo, Barbara, Pace, Annese, Bassotti, Binda, Casetti, Colecchia, 
Festi, Fiocca, Laghi, Maconi, Nascimbeni, Scarpignato, Villanacci & Annibale 2014) costing the 
health care system of the United States of America (USA) an estimated 2.7 billion dollars per 
year.  Annually, approximately 313 000 patients with DD require surgical intervention or 
hospitalization (Peery, Barrett, Park, Rogers, Galanko, Martin & Sandler 2012; Peery & Sandler 
2013).  In SA, an increased prevalence of DD has been noted in the urbanized SA black 
population, compared to the rural SA black population (Weizmen and Nguyen 2011).  
 
Although diet plays an important role in the management of DD, the two dietary approaches are 
completely opposed (Tarleton & DiBaise 2011).  The traditional restrictive low fiber diet 
recommends the avoidance of insoluble fiber including nuts, seeds, popcorn and corn while the 
ICCG (Tarleton & DiBaise 2011; Andersen, Bundgaard, ElbrØnd, Laurberg, Walker, StØvring 
2012; Pietrzak, Mik, Bartnik, Dziki & Krokowicz 2013; Cuomo et al 2014; Royal College of 
Surgeons Advancing Surgical Standards 2014) advocate a liberal unrestricted (HFD) (Crowe, 
Balkwill, Cairns, Appleby, Green, Reeves, Key & Beral 2014).  Although the ICCG have 
concluded that the consumption of nuts, seeds and popcorn does not appear to exacerbate DD 
symptoms/complications (Strate, Liu, Syngal, Aldoori & Giovannucci 2008), there has been 
anecdotal evidence that their inclusion may worsen symptoms and provoke attacks in some 
(National Health Service 2015).  This raises the question of whether the ICCG advocating a 
liberal HFD, are appropriate for all those with DD, as Salzman & Lillie (2015) commented that 





The favorable manipulation of the gut bacteria via the prebiotic impact of fiber may offer an 
important benefit (Donini, Savina & Cannella 2009), as probiotics may play an important role in 
reducing localized inflammation in SUDD, possibly preventing attacks of diverticulitis (Tursi, 
Brandimarte, Giorgetti & Elisei 2006; Quigley 2010).  
 
It was important to establish the beliefs and practices of dietitians treating SUDD to determine 
whether, based on their experience, they agreed with the ICCG despite anecdotal evidence which 
suggested that the liberal HFD may not benefit all.  As the use of both prebiotics and probiotics is 
currently not addressed by the ICCG, it was important to determine whether, based on practical 
experience, RDs felt that these offered a therapeutic advantage.   
 
1.2 STATEMENT OF THE RESEARCH PROBLEM 
 
Current approaches to the dietary treatment of SUDD are contradictory as outlined below: 
 
1.2.1 the consensus statements have concluded that the consumption of nuts, corn and popcorn 
does not appear to exacerbate SUDD (Strate et al 2008) 
1.2.2 anecdotal evidence indicates that the inclusion of insoluble fiber including nuts, popcorn 
and corn, in the diet of a patient with SUDD may worsen symptoms and provoke attacks 
in some (National Health Service 2015).   
1.2.3 the favorable manipulation of the gut bacteria via the prebiotic impact of fiber may offer 
an important benefit (Donini, Savina & Cannella 2009) as probiotics may play an 
important role in reducing localized inflammation in SUDD possibly preventing attacks 
of diverticulitis (Tursi et al 2006; Quigley 2010). 
 
This raises the question of whether the ICCG, advocating a liberal HFD, are appropriate for all 
those with SUDD as Salzman & Lillie (2005) commented that patients with SUDD often mention 







1.3 RESEARCH OBJECTIVES  
 
1.3.1 To determine whether RDs in SA agreed with the ICCG. 
1.3.2 To determine whether RDs in SA supplemented with fiber in the treatment of SUDD. 
1.3.3 To determine whether RDs in SA identified specific foods believed to trigger attacks in 
SUDD. 
1.3.4 To determine whether RDs in SA supplemented with prebiotics and/or probiotics and 
other nutritional supplements. 
1.3.5 To determine whether RDs in SA believed that their dietary approach was successful. 
 
1.4 NULL HYPOTHESIS 
 
1.4.1 Registered dietitians in SA would not agree with the ICCG in treating SUDD. 
1.4.2. Registered dietitians in SA would recommend a liberal unrestricted HFD in SUDD 
patients.  
1.4.3. Registered dietitians in SA did not believe in specific trigger foods in SUDD. 
1.4.4. Registered dietitians in SA would not supplement with prebiotics and/or probiotics and 
other nutritional supplements. 
1.4.5.   Registered dietitians in SA would not believe that their dietary approach was successful. 
 
1.5 STUDY PARAMETERS 
 
1.5.1 Inclusion criteria  
 
All RDs who had treated or who were currently treating SUDD in SA. 
 
1.5.2 Exclusion criteria 
 






1.6 ASSUMPTIONS  
 
1.6.1 Registered dietitians treated SUDD in SA according to the ICCG. 
1.6.2 Registered dietitians had access to the internet. 
1.6.3 Registered dietitians were fluent in English.  
1.6.4 The DD letter (Appendix B), which consisted of information regarding the study and a 
consent note, was sent out via the Association for Dietetics in South Africa (ADSA) 
webmail newsletter and it was assumed that all ADSA members would read the letter.  
1.6.5 Registered dietitians would respond to and answer the questionnaire honestly.  
 
1.7  DEFINITION OF TERMS  
 
Acute diverticulitis An acute episode of severe, prolonged, lower abdominal pain (usually on 
the left side), change in bowel movement, low-grade fever and 
leukocytosis (Cuomo et al 2014). 
 




Patients with diverticula and the absence of any sign or symptoms of 
diverticular inflammation (Tursi 2010). 
 
Balsalazide An anti-inflammatory drug converted to mesalazine in the body (Tursi, 




Patients with diverticula who experience symptoms and demonstrate 
signs of diverticular inflammation with further complications 









Dietitian A dietitian prescribes a healthy diet which may help prevent or treat 
diseases or illnesses (Medical-dictionary 2016). 
  
Diverticula Herniation of the mucosa through weak areas of the colonic wall (Peery 
et al 2012). 
 
Diverticular disease Diverticula associated with symptoms (Janes, Meagher & Frizelle 2006). 
 
Diverticulitis Evidence of diverticular inflammation (fever, tachycardia) with or 
without localized symptoms and signs (Janes et al 2006). 
 
Diverticulosis The presence of colonic diverticula within the colon (Murphy, Hunt, 
Fried & Krabshuis 2007; Elisei & Tursi 2016), these may become 
symptomatic or complicated (Cuomo et al 2014). 
 
Faecal stasis Faecal material stagnating or not moving through the intestine (Sheth & 
Floch 2009). 
 
High fiber diet A high dietary intake of insoluble and soluble fiber foods that are 
resistant to digestion in the gut (Anderson, Baird, Davis, Ferreri, 
Knudtson, Koraym, Waters & Williams 2009). 
 
Incidence   The probability of a person being diagnosed with a new disease within a 
given period of time (New York State Department of Health 1999). 
 
Insoluble fiber  Insoluble fiber is indigestible fiber that is unable to be broken down by 
digestive enzymes and juices in the human gut.   Insoluble fiber passes 
through the small intestine and colon undigested, increasing faecal mass.  
Examples include: corn fiber, wheat bran (Petruzziello, Iacopinin, 







A mixture of oligosaccharides and xylose residue that act as a prebiotic 
in the gut (Aachary & Prapulla 2010). 
 
Prebiotic A non-digestible food ingredient that acts as a substrate for desirable 
bacteria helping to stimulate their growth and/or activity thereby 
improving the health of the host (Slavin 2013). 
 
Probiotic Viable micro-organisms which, when ingested, might exert beneficial 
effects in the prevention and treatment of a number of specific 
pathological disorders (Lamiki, Tsuchiya, Pathak, Okura, Solimene, Jain, 





Patients with diverticula who experience recurrent symptoms (more than 
one attack per year) but without signs of diverticular inflammation (Tursi 
2010). 
 
Rifaximin A broad spectrum, poorly absorbable antibiotic that is able to act on 
Gram-negative and Gram-positive bacteria, both aerobic and anaerobic 
(Elisei & Tursi 2016). 
 
Soluble fiber Soluble fiber contains viscous fibers that are able to dissolve in water, 
forming a gel like substance and most are able to ferment in the colon. 
Examples are: psyllium, ispaghula, calcium polycarbophil (Petruzziello 





Patients with diverticula who experience symptoms such as abdominal 
pain (bloating, change of bowel habits and constipation/diarrhea) without 









ADSA Association for Dietetics in South Africa 
AGA American Gastroenterological Association 
AIDS Acquired immunodeficiency syndrome 
DD Diverticular Disease 
DNA Deoxyribonucleic acid 
FODMAP Fermentable, Oligo-, Di-, Mono-saccharides And Polyols 
FOS Fructo-oligosaccharides 
GALT Gut associated lymphoid tissues 
GOS Galacto-oligosaccharides (GOS), 
HFD High fiber diet 
HIV Human immunodeficiency disease 
HPCSA Health Professional Council of South Africa 
IBD Irritable Bowel Disease 
ICCG International Current Consensus Guidelines 
KZN KwaZulu-Natal 
MCG Millennium Criteria Goals 
NHS National Health Service 
RCS Royal College of Surgeons  
RCT Randomised control  
RDs Registered dietitians 
SA South Africa 
SA DoH South African Department of Health 
SCFA Short chain fatty acids 
SUDD Symptomatic Uncomplicated Diverticular Disease 
TB Tuberculosis 
UKZN University of KwaZulu-Natal 
USA United States of America 





1.9  SUMMARY 
 
The dietary approach used in the treatment of DD patient’s in-between acute attacks is 
confounding as the paucity of good quality evidence is lacking.  The current dietary ICCG 
recommend a HFD that includes insoluble fiber compared to the traditional guidelines where a 
low insoluble fiber diet was promoted.  Anecdotal evidence contradicts the new dietary 
guidelines as internet support groups have patients reporting that their symptoms regress when 
changing from the traditional to current approach.  As there are diametrically opposed treatment 
guidelines, it was important to establish what dietary approaches dietitians used to treat DD in-
between acute attacks, if they believed their approach to be beneficial and to determine if there 
























CHAPTER 2: LITERATURE REVIEW 
 
2.1  INTRODUCTION  
 
Diverticular disease is one of the most common colon diseases experienced in Westernized 
countries  (Naidoo 2009; Tursi 2013; Pisanu, Vacca, Reccia, Podda & Uccheddu 2013) and 
effects the elderly population with the prevalence being common in approximately 65% of people 
over the age of 65 (Guslandi 2013).  In the last 20 years, 313 000 diverticular patients have been 
hospitalized in the United States of America (USA) (Peery et al 2012) resulting in a 16% increase 
in surgical interventions, hospital admissions (Janes et al 2006) and costing 2.7 billion dollars 
(Peery & Sandler 2013). The devastating impact on health includes life threatening complications 
such as perforation, obstruction and haemorrhaging (Tarleton & DiBaise 2011; Peery et al 2012).  
Although the current prevalence in SA is unknown, Weizmen & Nguyen (2011) showed that 
urbanized SA black men had an increased risk of developing the disease. 
 
In the management of SUDD, there is consensus that the best therapeutic approach is to prevent 
relapse (Tursi 2013; Mosadeghi, Bhuket & Stollman 2015), however, the dietary management 
remains controversial (Tarleton & DiBaise 2011).  Traditionally the avoidance of dietary fiber, 
including nuts, seeds, corn and popcorn was advocated (Tarleton & DiBaise 2011).  Recent 
ICCG take an opposing stance by advocating the inclusion of large amounts of all types of fiber 
(Tarleton & DiBaise 2011; Andersen et al 2012; Pietrzak et al 2013; Cuomo et al 2014).  Neither 
approach is based on substantial scientific literature (Tarleton & DiBaise 2011).  Although the 
unrestricted approach includes the general benefits of a HFD, anecdotal evidence on the National 
Health Service (NHS) website (2015) suggests that some SUDD sufferers may experience severe 
discomfort (constipation, abdominal pain or discomfort, diarrhoea) and benefit from fiber 
exclusion. 
 
The scope of this review includes the spectrum and pathophysiology of DD, the controversy 
surrounding the dietary treatment of SUDD and the potential therapeutic benefits of fiber (both 
soluble and insoluble) as well as prebiotics and probiotics.  Complicated DD is not part of the 




2.2 SPECTRUM OF DIVERTICULAR DISEASE  
 
The spectrum of DD initially begins with the development of diverticula.  Colonic diverticula are 
out-pouching’s or sac like protrusions found in weak areas in the circular muscle of the colon 
wall resulting in herniation (Marlett, McBurney & Slavin 2002; Peery & Sandler 2013; Elisei & 
Tursi 2016).  Diverticulosis is the presence of asymptomatic diverticula without inflammation 
(Wilkins, Embry & George 2013) (Figure 2.1).  Diverticular disease is a term used to signify 
diverticulosis with a complication (Peery & Sandler 2013) and diverticulitis refers to 
infected/inflamed diverticuli.  Out of the 20% who develop symptomatic DD, 85% develop 
SUDD with the remainder developing complicated DD (Elisei & Tursi 2016).  Symptomatic 
uncomplicated DD is usually characterized by abdominal bloating, nausea, changes in bowel 
habits, constipation and/or diarrhoea due to bacterial overgrowth  (Petruzziello et al 2006; Elisei 
& Tursi 2016).  
 
Figure 2.1:  The spectrum of diverticular disease (after Tarleton & DiBaise 2011; Peery 






















2.3 PATHOPHYSIOLOGY OF DIVERTICULAR DISEASE 
 
Although the pathophysiology is unknown, potential contributing factors include increasing age, 
genetics, inflammation and dietary contributors such as a low intake of dietary fiber and altered 
colonic microbiota (Commane et al 2009; Tarleton & DiBaise 2011; Ünlü, Daniels, Vrouenraets 
& Boermeester 2012; Ulmer, Rosch, Mossdorf, Alizai, Binnebösel & Neumann 2014). 
 
2.3.1 Dietary fiber 
 
Painter (1974) suggested that DD is a disease of Westernized civilization due to the intake of 
dietary fiber from cereal grains in the Western diet being low, compared to developing countries 
such as Africa, India and rural Asia, where fiber consumption is high and the disease is rare. 
Similarly, vegetarians and people who consume high amounts of fiber have a lower incidence of 
diverticula (Salzman & Lillie 2015).   
 
It has been hypothesized that a low fiber intake could increase the colonic intraluminal pressure 
and cause uneven thickening of the colonic muscular wall, leading to mucosal herniation 
resulting in diverticula formation (Painter 1974; Painter 1982; Janes et al 2006).  A low fiber diet 
reduces stool volume and increases the risk of developing constipation which may be a common 
cause in the development of colonic diverticula (Sheth & Floch 2009; Raahave 2015).  
Constipation promotes bacterial overgrowth resulting in chronic inflammation (Raahave 2015), 
increased production of mucus as well as increased strain (Painter 1982; Janes et al 2006).  A 
HFD, according to Painter (1974), produces less strain in the sigmoid colon and allows for the 
stools to pass through more easily.  This improves constipation and reduces diverticula 
development. 
 
The location of colonic diverticula vary in different parts of the world (Weizman & Nguyen 
2011).  In Western societies, 85% are located on the left side on the sigmoid and descending 
colon, supporting the theory that increased colonic intraluminal pressure plays an important role.  
However, diverticuli in Asian and Japanese Hawaiian communities are isolated on the right side 




larger in volume and the stools are unformed (Commane et al 2009; Ulmer et al 2014).  
Interestingly, right sided diverticula seem more likely to occur when a diet rich in fiber is eaten 
(Petruzziello et al 2006).  The high pressure hypothesis cannot explain why right sided 
diverticula develop in the proximal colon where muscular contraction is less and the bowel 
diameter is large (Peery et al 2012). 
 
2.3.2    Gut microflora 
 
Microflora homeostasis in the gut is critical as the microflora help to maintain the functioning 
and integrity of the epithelial lining in the gut, as well as promoting the development of gut 
associated lymphoid tissues (GALT) and gut motility (Quigley 2010).  Faecal stasis1 from 
prolonged colonic tranist time may cause bacterial overgrowth and alter the composition of the 
microflora in the diverticula (Narula & Marshall 2010).  This may impair mucosal barrier 
functioning and upregulate inflammatory cytokine release resulting in intestinal inflammation 
(Sheth & Floch 2009; Narula & Marshall 2010).  Inflammation from colonized bacteria or 
bacterial entrapment in the diverticula may cause symptoms in SUDD patients and could lead to 
acute diverticulitis (Quigley 2010). 
 
2.4     CONSENSUS GUIDELINES 
 
International Current Consensus Guidelines by respected organisations support the use of a HFD 
(Andersen et al 2012; Cuomo et al 2014; Pietrzak et al 2013; Royal College Services Advancing 
Surgical Standards 2014; Stollman, Smalley, Hirano & American Gastroenterological 
Association Institute Clinical Guideline Committee 2015).  The type of fiber (soluble versus 
insoluble) was not stipulated in any of the guidelines, although a general “high fiber diet” had 
been recommended by most.  The World Gastroenterology Organisation (WGO) (Murphy, Hunt, 
Fried & Krabhuis 2007) states that a diet low in dietary fiber may increase the risk of 
complications in DD.  The Consensus Guidelines from the Danish National Guidelines 
(Andersen et al 2012), the American Gastroenterological Association (AGA) (Stollman, Smalley, 
                                                





Hirano & American Gastroenterological Association Institute Clinical Guideline Committee 
2015), the Italian Consensus (Cuomo et al 2014), Polish Consensus (Pietrzak et al 2013) and 
Great Britain’s Royal College Services (RCS) commissioning guide (Royal College Services 
Advancing Surgical Standards 2014) all advocate the use of a HFD for individuals with SUDD.  
These ICGG, recommend a HFD, but none of them gave actual prescriptions regarding the 
amount of fiber that would be beneficial in SUDD patients.  The British National Health Services 
recommends a HFD (18g to 30g/day) including at least five vegetables and fruits a day (National 
Health Service 2015).  The Italian Consensus advises the intake of nuts, corn and popcorn 
(Cuomo et al 2014) as does the AGA 2015 Consensus (Stollman et al 2015).  Although the use of 
fiber supplements in SUDD has been mentioned in a few of the ICCG (Andersen et al 2012; 
Pietrzak et al 2013), the type of fiber to supplement with was not mentioned.  The Italian 
Consensus (Cuomo et al 2014) and the AGA (Stollman et al 2015) Consensus stated that fiber 
supplements are controversial in the treatment of SUDD, while the RCS commissioning guide 
(Royal College of Surgeons Advancing Surgical Standards 2014) and the WGO (Murphy et al 
2007) did not mention fiber supplementation at all.   
 
2.5 DIETARY TREATMENT 
 
Dietary approaches for the treatment of DD includes manipulation of fiber as well as 
supplementation with prebiotics and/or probiotics to favourably alter the gut microbiota (Donini 
et al 2009).  It is accepted that dietary fiber plays a role in the treatment of DD, although the type 
of fiber advocated is more controversial. 
 
2.5.1 Use of dietary fiber 
 
Dietary fiber is the undigested portion of food which passes into the colon (Buttriss & Stokes 
2008).  Although there are many classifications of dietary fiber, the division of fiber into the   
categories of insoluble and soluble fiber is commonly used (Anderson et al 2009). As fiber 
increases stool bulk, decreases transit time, reduces intraluminal pressure and has a prebiotic 
effect on gut microflora (Tarleton & DiBaise 2011), different types of fiber may play an 




2.5.1.1  Insoluble dietary fiber 
 
Insoluble dietary fiber is relatively resistant to being broken down during the digestive process 
which then creates a bulking action in the colon (Anderson et al 2009), decreases intestinal transit 
time, modulates water absorption, improves stool weight (Ho, Tan, Daud & Seow-Choen 2012) 
and reduces constipation.  Insoluble fibers include cellulose, lignin and some hemicelluloses 
(Buttriss & Stokes 2008; Tarleton & DiBaise 2011).  Foods that are rich in insoluble fiber include 
flax, rye, wheat bran, nuts, vegetables, legumes, fruit and fruit skins (Aldoori, Giovannucci, 
Rockett, Sampson, Rimm & Willett 1998; Tarleton & DiBaise 2011).  
 
2.5.1.2  Soluble dietary fiber  
 
Unlike insoluble fiber, most soluble fibers are viscous and are able to be fermented in the colon 
(Anderson et al 2009; Slavin 2013).  Fermentation in the colon is not exclusive to soluble fiber, 
as some insoluble fibers, such as resistant starch, may also be fermented in the colon although in 
general, insoluble fiber is fermented to a much lesser degree (Aldoori et al 1998; Buttriss & 
Stokes 2008).  Specific soluble fibers, such as pectin, psyllium, gums, beta-glucan, fructo-
oligosaccharide (FOS), galacto-oligosaccharide (GOS), wheat dextrin and inulin (Buttriss & 
Stokes 2008; Tarleton & DiBaise 2011; Slavin 2013) act as prebiotics, stimulating the growth of 
health producing bacteria such as Bifidobacteria and Lactobacilli, thereby favourably 
manipulating the microbiota.  These probiotics are able to stimulate the immune system, decrease 
the intestinal pH via the release of short chain fatty acids (SCFA), balance the colonic microflora 
and prevent pathogenic metabolism which in turn could reduce inflammation in SUDD patients 
(Anderson et al 2009; Tursi 2010).   
 
Foods that are rich in soluble fiber include legumes, oat bran, fruits (citrus fruit, apples, bananas, 
tomatoes), vegetables (onion, garlic, leeks, Jerusalem artichoke, asparagus), barley, psyllium and 
chicory (Aldoori et al 1998; Aldoori & Ryan-Harshman 2002; Floch & Hong-Curtiss 2002; 
Grajek, Olejnik & Sip 2005; Tarleton & DiBaise 2011; Slavin 2013).   Most contain some degree 




et al 1998; Aldoori & Ryan-Harshman 2002; Floch & Hong-Curtiss 2002; Grajek et al 2005; 
Tarleton & DiBaise 2011; Slavin 2013).   
 
The term dietary fiber has been used throughout many DD ICCG documents without 
specification of the type of fiber that may be more beneficial in SUDD (Andersen et al 2012; 
Cuomo et al 2014).   
 
2.5.2 Dietary fiber intake in symptomatic uncomplicated diverticular disease 
    
Historically, low insoluble fiber diets were believed to be the best form of treatment for DD 
(Painter 1982).  Patients were advised to eat a low insoluble fiber diet which excluded nuts, corn, 
popcorn and seeds as it was thought that these foods could become entrapped in the diverticula 
resulting in diverticulitis (Painter 1982).  However, high quality evidence supporting this 
approach is lacking (Ünlü et al 2012; Peery et al 2012). 
 
In a twenty-two month prospective uncontrolled intervention study by Painter, Almeida & 
Colebourne (1972), a HFD (All-Bran, Weetabix, wholemeal as opposed to brown bread, 
increased fruit and vegetables) supplemented with unprocessed bran (12 to 14g/day) with a low 
sugar intake, was initiated in SUDD patients (Table 2.1).  Of the 70 patients, 88.6% of their 
symptoms (dyspeptic2, lower or general abdominal pain, symptoms related to defecation, 
constipation) were relieved or abolished.  Only 3.8% did not experience any relief or their 
symptoms were not abolished.  An intake of 14g of bran avoided straining in 88.6% (62/70).  A 
very small percentage (5.7%) were unable to take the unprocessed bran as it caused the following 
symptoms; nausea, distention, left iliac fossa pain or ache, lower or general abdominal pain, 
severe colic or constipation.  The study by Painter (1972), however, lacked a control group and 
the study was uncontrolled, lowering the strength of the evidence.   
 
A six-month prospective, uncontrolled, intervention study by Brodribb & Humphreys (1976) 
assessed symptoms (dyspeptic, abdominal pain, symptoms related to defecation, constipation) in 
40  patients  with  SUDD  (Table 2.1).   Patients were instructed to supplement with 24g of wheat 
                                                
2 Dyspeptic symptoms measured in Painter et al 1972, Brodribb & Humphreys (1976) and Ornstein et al (1981) were nausea,  




















22 months 70 SUDD pts received a high 
fiber diet with unprocessed 
bran (12-14g/day) plus low 
sugar intake. 
88.6% (62/70) experienced 
significant reduction of 










6 months 40 SUDD patients were given 
24g wheat bran 
supplement/day in addition 
to normal diet.  
60% (24/40) of symptoms 
were abolished and 28% 

















20 SUDD pts were given a high 
fiber diet plus extra 
unprocessed bran where 
possible or  
Normacol and antispasmodic 
or 18g bran tablets/day. 
 
 
With each treatment, all 
patients experienced some 
improvement in symptoms. 
Bran tablets: 60% (12/20) 
entirely symptom free. 
Normacol: 40% (8/20) entirely 
symptom free. 
High fiber diet: 20% (4/20) 




















out period.  
58 SUDD pts were split into 3 
treatment groups  
Group A: 8 bran biscuits 
(4.2g fiber) & placebo. 
Group B: Ispaghula powder 
(6.7g fiber) & placebo 
biscuits. 
Group C: placebo biscuits 
and placebo powdered drink. 
Both dietary fibers reduced 
constipation but neither 
resulted in any improvement 
in symptoms and ispaghula 











56 SUDD pts were given a high 
fiber diet >25g/day or 
non-high roughage diet 
<25g/day. 
 
High fiber diet: fewer 
symptoms such as pain and 
constipation was relieved, 
lower re-admission with 
complications and surgery 







18 years 47 228 Diet, lifestyle and medical 
information was used to 
investigate the relationship 
between nuts, popcorn, and 
corn in being able to reduce 
diverticulitis occurrence. 
No association of diverticulitis 
occurrence in patients 








12 years 2104 Diet assessed to determine 
whether a high fiber diet and 
frequent bowel movements 
prevent diverticulosis. 
A high fiber diet increased the 
occurrence of diverticulosis. 
A high fiber diet and > 7 
bowel movements per week 
increased the risk of 
developing diverticula. 




bran (Prewett’s) per day in addition to their normal diets.  The results showed that 83% (33/40) 
were extremely satisfied with the bran supplement, 60% of symptoms were abolished and a 
further 28% of symptoms were reduced.  Five patients (13%) still had some form of abdominal 
discomfort and only a  slight  improvement  was  noticed  in  two of the patients (5%) at the end 
of the study.  The bran modified the transit time to a mean of 48 hours (p<0.006), increased stool 
weight from 23g to a mean of 66g to 89g (p<0.0002) and reduced intraluminal pressure during 
(p<0.003) and after eating (p<0.0001).  The authors concluded that an increased fiber intake 
relieved symptoms in SUDD.  The study had a small sample size and it did not contain a control 
group, reducing the quality and evidence of the study (Brodribb & Humphreys 1976).   
 
In a two-month randomised, crossover trial (RCT), Taylor & Duthie (1976) investigated the 
effect of fiber supplements in 20 patients with SUDD (Table 2.1).  Three standard regimes were 
implemented; a HFD plus extra unprocessed bran, where possible or Normacol3 (sterculia4) and 
an antispasmodic; or bran tablets supplying 18g bran per day.  Those on the HFD were told to eat 
high fiber foods, were given a dietary sheet containing the information and asked to supplement 
their diets with unprocessed bran, where possible.  The actual amount of unprocessed bran was 
not specified in the study.  A quarter took the HFD plus unprocessed bran for one month and a 
quarter took Normacol plus an antispasmodic for one month.  The others were given the bran 
tablets for a month.  
 
Treatments were then crossed over for another month whereby those who had taken the bran 
tablets initially received the HFD or Normacol for a month, while the others were given the bran 
for a month.  There was no wash out period during the study.  Symptoms (degree of pain, bowel 
habits, distention), stool weight and transit time were measured at the start, at cross over and at 
the end of the study.  The most effective were the bran tablets with 60% being entirely symptom 
free, followed by the Normacol (40%) and lastly the HFD plus unprocessed bran supplements 
(20%).  Some improvement in symptoms was noted in all the patients within each treatment 
group.  Stool weight had significantly increased after one month on either the bran tablets or 
Normacol and the transit time improved considerably in individual patients taking the bran 
                                                
3 The dosage for the Normacol was not given in the article by Taylor & Duthie (1972). 
 




tablets compared to either the HFD (p<0.001) or Normacol (p<0.05).  The mean transit time 
before treatment was 96.6 ± 7.1 hours and with bran tablets, the transit time reduced to 56.1 
hours.   The challenge with the Taylor and Duthie (1976) study was that it did not include a 
washout period therefore the impact of the various treatments was not clearly separated and could 
have impacted the results.  Other problems with the study was that eight patients who had 
recently had an acute diverticulitis attack were included, the study was not double-blind and no 
high versus low fiber diet was assessed during the study (Taylor & Duthie 1976).   
 
A twelve-month randomised, cross-over, double-blind controlled trial consisting of 58 patients 
with SUDD was conducted by Ornstein, Littlewood, Baird, Fowler, North & Cox in 1981 (Table 
2.1).  A self-administered questionnaire that measured patient’s symptoms (abdominal pain, 
symptoms related to defecation, constipation, dyspepsia) was given at baseline, monthly and at 
the end of the study to all patients.  Patients were told to follow their normal diets without 
including extra fiber besides that which was prescribed in the study.  Two forms of dietary fiber 
and two placebos were used in the study.  The placebos consisted of Energen wheat crispbread 
and a highly refined wheat powder.   
 
Patients were divided into three treatment groups:  group A took 8 bran biscuits containing 4.2g 
of fiber (Energen bran crispbread, an insoluble fiber) plus two sachets of placebo powder per day, 
group B was given eight placebo biscuits with two sachets of powdered ispaghula husk (Fybogel, 
a soluble fiber that consisted of 6.7g fiber) consumed daily and group C consisted of eight 
placebo biscuits and two sachets of placebo powder, given daily.  Each treatment was taken for 
sixteen weeks and all patients were subsequently treated to the three treatment periods with a 
cross-over period that neither the patient nor the physician was aware of.  No wash out period 
was given between treatments.  The study found that neither of the dietary fiber supplements had 
any effect besides reducing constipation (p<0.01) although ispaghula resulted in increased 
flatulence (p<0.05).  Although Ornstein et al (1981) believed that the use of fiber supplements in 
those with constipation may be helpful for the management of overall patient symptoms, fiber 





In comparison to Ornstein et al (1981) study, Painter et al (1972), Brodribb & Humphreys (1976) 
and Taylor & Duthie (1976), all showed a positive outcome in reducing or eradicating over 60% 
of symptoms (dyspeptic, abdominal pain, symptoms related to defecation, constipation) in most 
SUDD patients receiving a HFD and/or a bran supplement on a daily basis.  The fiber intake in 
these three studies (Painter et al 1972; Brodribb & Humphreys 1976; Taylor & Duthie 1976) was 
three to six times higher than that prescribed by Ornstein et al (1981).  Taylor & Duthie (1976) 
supplemented for a shorter period of time compared to Ornstein et al (1981) and still managed to 
show a significant reduction in symptoms from the higher bran supplement.  Ornstein et al (1981) 
had the strongest study design however it did lack a wash out period, as did Taylor & Duthie 
(1976), reducing the efficacy of their results.   
 
Leahy, Ellis, Quill & Peel (1985) prospective, case-controlled study assessed 56 SUDD patients 
who were allocated to a HFD (>25g/day) group (31/56) or non-HFD (<25g/day) group (25/56) 
(Table 2.1).   An average follow-up for the HFD group was 54 months and 76 months in the non-
HFD group.  A medical and dietetic staff member counselled those on the HFD and each was 
supplied with a booklet recommending a minimum intake of 25g of fiber per day. Those on a 
HFD experienced fewer symptoms (19%, 6/31) such as abdominal pain and altered bowel habits 
(constipation) in contrast to those on the non-HFD (44%, 11/25) (p<0.05).  There was a 
significantly lower rate of re-admission with complications and surgery (2/56 for the HFD versus 
8/56 for the non-HFD group) (p<0.05).   
 
Leahy et al (1985) concluded that a HFD favouring 20-25g/day dietary fiber reduced symptoms, 
constipation and those on a HFD were less likely to develop complications or require surgery.  
This was different to Ornstein el al (1981) study whereby a HFD was only seen to reduce 
constipation and no other symptoms although, the time frame for fiber supplementation in 
Ornstein et al (1981) study (16 weeks per treatment group) was much shorter than Leahy et al 
(1985) study (54-76 months).  The problem with Leahy et al (1985) study is that it measured the 
HFD (54 month) 24 months earlier to the non-HFD (76 months), which may have resulted in 





In 2008, Strate et al conducted a cohort prospective observational study investigating the 
consumption of nuts, popcorn and corn in 47 228 United States male health professionals aged 40 
to 75 years (Table 2.1).  Excluded from the study were men that had irritable bowel disease 
(IBD), cancer other than non-melanoma cancer and those with already existing diverticulosis or 
DD.   A self-administered semi quantitative, validated food frequency questionnaire as well as a 
lifestyle and medical history questionnaire was sent out to the men at baseline and then every 
four years.  Within the eighteen-year follow-up study, 801 incidences of diverticulitis (1.7%) and 
383 incidents (0.8%) of diverticular bleeding were recorded.  The study found no association 
with diverticulitis and diverticular bleeding in patients with diverticulosis who consumed nut, 
popcorn and corn during that time.  The consumption of a higher amount of nuts, popcorn and 
corn lowered the risk of diverticulitis occurrence (p=0.034) and according to Strate et al (2008), 
these foods do not invoke diverticular complications and should not be avoided in DD.  It has 
been assumed in the past that these foods may provoke symptoms in DD patients and lead to 
diverticulitis (Painter 1982) although Strate et al (2008) prospective study appears to demonstrate 
otherwise.   The short fall of Strate et al (2008) study is that it looked at men with a mean age of 
between 40-75, it did not assess woman and symptoms such as abdominal pain, abdominal 
discomfort and constipation were not measured. 
 
Peery et al (2012) conducted a cross-sectional, observational study over a twelve-year period on 
2104 asymptomatic diverticulosis participants between the ages of 30-80 years whereby the diet 
was assessed using the Block Diet History food frequency questionnaire which looked at 100 
food items (Table 2.1).  The results showed that a mixed HFD including high grain fiber, 
insoluble fiber and soluble fiber had an increased rather than a decreased prevalence of 
diverticula occurrence (p=0.004) and more frequent bowel movements (greater than 7 per week) 
increased the risk of diverticulosis (p<0.001).  Constipation is thought to increase the risk of 
developing diverticulosis but a reduction in stool movement in Peery et al (2012) study showed 
the opposite response. Tursi (2010) and Peery et al (2012) both mentioned that diverticulosis 
could lead to complications and increase morbidity.  Most of the studies mentioned in Table 1 
(Painter et al 1972; Brodribb & Humphreys 1976; Taylor & Duthie 1976; Ornstein et al 1981; 
Leahy et al 1985;) provided evidence that a HFD reduces abdominal symptoms and/or 




In a systematic review by Ünlü et al (2012), the treatment of SUDD with the inclusion of a HFD 
was reviewed. Studies that did not have a control group were excluded.  Out of the thirteen 
studies, only four met the inclusion criteria (Ünlü et al 2012), two of which have been previously 
discussed (Ornstein et al 1981; Leahy et al 1985).  A mix of fiber supplements was used 
including bran crisp bread (6.7g/day; Brodribb5 1977), bran (4.2g/day) and ispaghula (6.7g/day) 
(Ornstein et al 1981), methylcellulose (1 g/day; Hodgson6 1977) and a HFD (25g fiber/day) 
(Leahy et al 1985).  The conclusion stated that inconsistent results were obtained in the studies 
by Brodribb (1977), Ornstein et al (1981) and Hodgson’s (1977) and that the studies had small 
sample sizes.   Most of the evidence was inconsistent level two and level three evidence, 
therefore high quality evidence was lacking when recommending a HFD diet in the treatment of 
SUDD (Ünlü et al 2012)7.   
 
A more recent review which assessed fiber intake in diverticulosis and SUDD by Elisei & Tursi 
(2016) included the three RCT studies found in the Ünlü et al (2012) review as well as the three 
prospective cohort studies by Leahy et al (1985); Strate et al (2008), Crowe et al (2014) and the 
cross-sectional study conducted by Peery et al (2012).   In contrast to Ünlü et al (2012), Elisei & 
Tursi (2016) concluded that there was adequate quality controlled studies to advise using a HFD 
in SUDD. However, Crowe et al (2014) and Strate et al (2008) prospective studies did not 
measure a range of symptoms in patients (dyspeptic, abdominal pain, symptoms related to 
defecations) and yet they had been compared with other research on the use of SUDD.  The two 
reviews came to two different conclusions, one using more rigorous and controlled studies with a 
control group (Ünlü et al 2012), while the other included prospective studies (Elisei & Tursi 
2016).   Ünlü et al (2012) did point out that epidemiological and observational studies are 
confounding as they lack recent evidence on the prevalence of DD in different populations.  
Strate et al (2008) relied heavily on association which was different to causation when analysing 
research and should be viewed with caution in epidemiological studies (Geneva Foundation for 
Medical Education and Research 2016).  Depending on the interpretation of the available 
                                                
5 The following journal article was unobtainable:  Brodribb, A.J.  (1977).   Treatment of  diverticular disease  with a high fiber  
   diet.  Lancet 1:664-666. 
 
6  The following journal article was unobtainable:  Hodgson, W.J.  (1977).  The  placebo effect.  Is  it  important in diverticular     
   disease.  American Journal of Gastroenterology 67(2): 157-162. 
 
7  Level 1 evidence is based on high quality evidence such  as  randomised  controlled  trials  (RCT)  (Practicing Chiropractors’   




evidence, there seems to be controversy as to whether a HFD and/or fiber supplements are the 
best form of treatment in SUDD.    
 
The evidence supporting the prescription of insoluble fiber from nuts, popcorn and corn appears 
to be mostly based on the study by Strate et al (2008).  Tursi (2013) expressed concern as to how 
one study could have had such an impact on most of the research presented in the current 
literature and how based on this one study, many reviews and ICCG have advocated the use of 
these types of insoluble fiber foods.  
 
The anecdotal evidence and experience of both patients and medical community cannot be 
overlooked.  Strate et al (2008) citing Schechter, Mulvey & Eisenstat (1999) 8 found that 
approximately 47% of colorectal surgeons believed that avoiding nuts, corn and popcorn were of 
importance as these foods might incite diverticulosis complications.   
 
Anecdotal evidence from dietitians in practice and from patients support groups have suggested 
that some are sensitive to certain insoluble fiber rich foods, such as whole meal bread, nuts, fruit, 
shredded coconut and generally following a HFD (National Health Service 2015; Thompson 
2016).  Patient’s comments posted on the NHS site strongly stated that their symptoms were 
much worse since including certain trigger foods such as insoluble fiber, nuts, popcorn and that 
they were returning to the old approach (National Health Service 2015).  
 
The idea that one approach fits all seems to be lacking in scientific evidence and requires further 
investigation.  This is why the current study is important as it may provide a more accurate idea 
of what dietitians are currently prescribing compared to the ICCG.  It also helps to clarify based 
on practical experience, whether certain trigger foods and/or fiber supplements and/or a HFD are 
beneficial in reducing SUDD in clinical practice. 
 
Insoluble and soluble fiber may play an additional role as a prebiotic stimulating the growth of 
probiotics and positively manipulating the gut microbiota. 
 
                                                
8 The following article was unobtainable:  Schechter, S., Mulvey, J. & Eisenstat, T.E. (1999).  Management of uncomplicated  




2.6 GUT MICROBIOTA  
 
2.6.1 Microbiota in the healthy individual 
 
Microbiota are compounds that are able to produce vital nutrients (Silva, Carneiro, dos Anjos 
Pultz, Pereira Silva, Lopes & dos Santos 2015) in the gut.  These microbiotas have a symbiotic 
relationship in the gut, providing homeostasis between the residing host and the microbes (Silva 
et al 2015).  The colon is home to a large complex community of bacteria and greater than 95% 
of the two most prominent bacterial phyla are Bacteroides and Firmicutes (Silva et al 2015; 
Daniels, Budding, de Korte, Eck, Bogaards, Stockmann, Consten, Savelkoul & Boermeester 
2014). Other common bacteria phyla include Actinobacteria, Fusobacteria, Verrucomicrobia and 
Proteobacteria (Silva et al 2015).     
 
2.6.2 Microbiota in diverticular disease  
 
Increased bacterial populations of certain phyla, such as Escherichia (Proteobacteria), 
Clostridium (Firmicutes), and Bacteroides have been identified in patients with uncomplicated 
DD (Pietrzak et al 2013).  A dysbiosis of these bacteria and other Proteobacteria may cause a 
negative shift in the microbiota composition in DD which may in turn, stimulate inflammation of 
the diverticulum causing diverticulitis (Pietrzak et al 2013; Daniels et al 2014).  
 
In a multi-center RCT, faecal microbiota had been analysed using deoxyribonucleic acid (DNA) 
extraction obtained from rectal swabs, taken from 31 patients with uncomplicated acute 
diverticulitis (mean age of 58 years) and 25 controls (mean age of 53 years) (Daniels et al 2014).  
The results showed that the Firmicutes/Bacteroidetes ratio were similar in the patient and the 
control group.  This indicates that there was no dysbiosis between these two phyla as the 
Firmicutes/Bacteroidetes ratio is used as an indicator of gut microbiota dysbiosis (Daniels et al 
2014).  A higher diversity of faecal microbiota, however, was noted in the DD versus the control 
group.  Proteobacteria, gram-negative bacteria that are more prevalent in disease conditions 




more prevalent in DD compared to the control group (Daniels et al 2014; Goel, Gupta & 
Aggarwal 2014).  
 
Inflammation is thought to be implicated in DD as microbial changes may cause disturbances on 
the tissue and mucous membranes surrounding the diverticuli, causing proliferation of 
inflammatory cytokines, which in turn can create a chronic inflammatory effect (Sheth & Floch 
2009; Tursi 2010; Pietrzak et al 2013).  The increased release of inflammatory cytokines, colonic 
bacterial overgrowth, mucous secretion and impaired mucosal barrier function may result from 
the diverticula being exposed to faecal stasis (Sheth & Floch 2009).  Faecal stasis may cause 
distention and erosion in the colon, enabling bacterial translocation and eventual perforation 
(Figure 2.2) (Janes et al 2006; Sheth & Floch 2009; Pietrzak et al 2013).  
 
 
Figure 2.2: Faecal obstruction leading to inflammation, bacterial translocation and 
                              perforation  
 
Altered microbiota, low levels of inflammation and altered mucosal defences in diverticulosis 
may predispose patients to acute diverticulitis (Sheth & Floch 2009).  Manipulation of the gut 
flora with viable probiotic bacteria has been proposed as a therapeutic option in the treatment of 



























Probiotics are live organisms that have a positive impact on the health of the host (Sheth & Floch 
2009) by successfully competing with other microbes, thus preventing their growth or that of 
other pro-inflammatory organisms (Lamiki et al 2010) (Figure 2.3).  Probiotics help to provide a 
mucosal defence on the epithelial lining thereby limiting or inhibiting translocation and 
adherence of pathogens (Lamiki et al 2010).  Probiotics also improve immune function and 
reduce concentrations of pro-inflammatory cytokines such as interleukin 1 (IL-1), tumour 
necrosis factor-alpha and interferon gamma (Tursi et al 2007; Lamiki et al 2010; Quigley 2010; 
Verna & Lucak 2010).  Some probiotics produce certain agents that are able to kill or inhibit the 
growth of certain microorganisms which may be as effective as antibiotics (Lamiki et al 2010).  
Antibiotics, frequently used in the treatment of SUDD, do not offer the additional benefits of gut 
homeostasis, pH alteration and suppression of pro-inflammatory cytokines (Figure 2.3) (Lamiki 
et al 2010; Narula & Marshall 2010).  
 
 


















Certain probiotic strains such as Lactobacillus and Bifidobacteria stimulate the immune system 
and decrease intestinal pH by releasing SCFA (acetate, butyrate and propionate) which in turn 
inhibits the growth of certain pathogens (Anderson et al 2009; Slavin 2013; Goel et al 2014; 
Silva et al 2015).  Short chain fatty acids are found in the distal colon, a common site affected by 
DD and are able to enhance epithelial barrier function, enable epithelial restoration and are an 
important fuel source for the colon (Aldoori et al 1998; Goel et al 2014). 
 
2.7.1 Use of probiotics in the treatment of diverticular disease 
 
Probiotics have been investigated for microbial interface treatment as an alternative or adjunct for 
antibiotic use in SUDD.  Gram negative flora are usually treated by antibiotic use in DD patients 
but probiotic bacteria are able to regulate certain enteric pathogens (Bengmark 1998).  Current 
research in SUDD has investigated antibiotics, probiotics or a mixture of both (Lamiki et al 2010; 
Narula & Marshall 2010). 
 
Frič & Zavoral (2003) presented the first prospective, nonrandomized, open-labelled pilot study 
which investigated antimicrobial and probiotic use in fifteen SUDD patients who experienced 
abdominal discomfort (Table 2.2).  The pilot study used dichlorchinolinol (an antimicrobial) and 
an absorbent (active coal tablet) for a week in treatment group one (T1).  When the T1 group 
experienced a relapse in symptoms, the same antimicrobial and absorbent were administered 
again to the same T1 group.  In addition, a probiotic called Escherichia coli Nissle 1917 
(2.5x1010 viable bacteria in capsule form) was administered for a further five weeks and two 
days, creating treatment group two (T2).   One probiotic capsule was given daily on days one to 
four and two capsules daily from day five.  Eight out of fifteen patients (T2) were symptom free 
at the end of the study and a significant decrease of all symptoms was observed with probiotic 
use (p<0.001).   The remission rate was much longer in those administered probiotics (14.1 
months) versus patients who received the antimicrobial and an absorbent (2.4 months) (p<0.001).  
The study did not include a probiotic only treatment group, the sample size was small and the 





A multi-center, prospective, randomised, open-label study by Tursi et al (2006) evaluated the use 
of Lactobacillus casei subsp. DG with or without the use of mesalazine (an amino salicylate anti-
inflammatory drug) in SUDD patients (Table 2.2).  Lactobacillus casei subsp. DG was chosen for 
its high antimicrobial effect, especially against gram negative bacteria such as Helicobacter 
pylori and its ability to improve and maintain human intestinal colonization (Tursi et al 2006).  
Eighty five patients took part in the twelve month study and were divided into three groups; the 
M group was given 1.6 g mesalazine per day, the L group was given two capsules daily each 
containing Lactobacillus  casei  subsp.  DG (8 by 109  viable lyophilized bacteria)  plus a vitamin 
cocktail (Vitamin B1, B2, B6) for fifteen days per month and the LM group were given 
mesalazine 1.6 grams per day plus 16 by 109   Lactobacillus casei subsp. DG for fifteen days per 
month.  There was no reason given for the fifteen-day implementation of mesalazine, probiotic 
and the cocktail vitamin mix; dietary intervention was also not provided.  Symptoms such as 
constipation, diarrhoea, abdominal pain, rectal bleeding and mucus with the stools were evaluated 
on enrolment and at the end of the first, second, ninth and twelfth month.  The results showed 
that 76.7% in both group M and Group L (p<0.001) were symptom free, hence, the probiotic with 
the vitamin cocktail was as effective as the medication.  In the LM group, 96% were symptom 
free therefore the probiotic in combination with the medication as well as the probiotic with the 
vitamin cocktail appeared to have had a synergistic effect.  There was a statistical significance 
obtained from group LM versus group L and group M (p<0.05).  The Tursi et al (2006) study 
concluded that both mesalazine and probiotics seemed to have a beneficial effect in preventing 
the recurrence of SUDD.  The results, however, were not directly comparable as the study did not 
contain solely a probiotic group, making it difficult to distinguish which factor (vitamin cocktail, 
mesalazine, probiotic) played a significant role in reducing symptoms.  In addition, the study was 
not blinded, weakening the outcome (Tursi et al 2006). 
 
An open label, randomised study by Tursi et al. (2007) compared the efficacy of probiotics 
versus balsalazide9 and rifaximin (antibiotic) versus probiotics in 30 SUDD patients with a mean 
age of 60.1 years, over a twelve-month period (Table 2.2).  Group A was given 2.25 g balsalazide 
and 800 mg rifaximin initially for ten days, followed by 2.25 g balsalazide for ten days plus 
VSL#3 (Lactobacillus plantarum DSM 24730, Lactobacillus acidophilus DSM 24735, Lactobaci- 
                                                
































and active coal tablet 
for 1 week. 
T2: dichlorchinolinol 
for 1 week and active 
coal tablet and probiotic 
daily.  
 





T2: 8/15  symptom 
free.  
T2: 14.1 months 
remission rate 
compared to 2.4 
months in T1 group. 








casei  subsp. 
DG 
M group: mesalazine 
1.6 g/day. 
L group: probiotic 15 
days/month plus 
vitamin cocktail. 
LM group: mesalazine 
1.6 g/day and probiotic 









M group: 76.7% 
(23/29) symptom free. 
L-group: 76.6% 
(23/29) symptom free. 
LM group: 100% 
symptom free (29/29). 





30 VSL #3  A Group: balsalazide 
2.25g and 800 mg 
rifaximin for 10 
days/month then 
followed by balsalazide 
2.25g for 10 day/month 
plus probiotics for 15 
days/month for 12 
months. 
B Group: balsalazide 
2.25g & 800 mg 
rifaximin for first 10 
days then for 15 
days/month probiotics 










symptom free (11/15). 
Group B: 60% (8/15) 
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Group A: High fiber 
diet (>30g/day) and 1 
sachet Flortec© /day 
Group B: High fiber 






Group A: 30 % 
reduction in 
abdominal bloating. 
Group A & B:  
significant reduction 
in abdominal pain. 















M group: active 
mesalazine 1.6 g/day 
and a probiotic placebo 
for 10 days/month. 
L group: mesalazine 
placebo and active 
probiotic for 10 
days/month.   
LM group: active 
mesalazine 1.6 g/day 
and active probiotic for 
10 days/month. 
P group: mesalazine 
placebo & probiotic 






















P group:  
46% (23/50) 
 
P group:  
12 % (6/50)  
L group: 
1.8% (1/55) 
No.=Number; pts=patients; SUDD= symptomatic uncomplicated diverticular disease 
 
llus paracasei DSM 24733, Lactobacillus delbrueckii subsp. bulgaricus DSM 24734, 
Bifidobacterium longum DSM 24736, Bifidobacterium breve DSM 24732, Bifidobacterium 
infantis DSM 24737, Streptococcus thermophiles DSM 24731) 450 by 109 per day for fifteen 
days, every month for twelve months.  Group B was primarily prescribed 2.25 g balsalazide and 
800 mg rifaximin for ten days, followed by VSL#3 probiotic, 450 by 109 per day for fifteen days 
every month over a twelve-month period.  Intensity of symptoms was assessed during the study.  
Rifaximin was used as it is effective against Gram-negative and Gram-positive bacteria, both 
aerobic and anaerobic as well as being an appropriate and effective antibiotic that is used in the 
treatment of SUDD (Tursi 2010; Elisei & Tursi 2016).  Symptoms included bloating, upper 
and/or lower abdominal pain, constipation, diarrhoea, rectal bleeding, mucous in the stools, 
abdominal tenderness and tenesmus.  In group A, 73.3% (11/15) (95% CI per-protocol: 55-92%; 
on intention-to-treat: 47%-87%) were symptom free, which was statistically significant compared 
to 60% (8/15) (95% CI per-protocol: 44-81%; on intention-to-treat: 39-76%) in group B. This 
showed that the combination therapy (monthly treatment of anti-inflammatory and probiotics) 




(probiotics intervention only) in the study, monthly probiotic use after the initial intake of 
balsalazide and rifaximin, was effective and did show a significant reduction in symptoms 
without the use of a monthly anti-inflammatory.  Tursi et al (2007) concluded that mucosal 
inflammation is suppressed in SUDD patients when using either probiotics and/or 
balsalazide/rifaximin.  A limitation of Tursi et al (2007) study was that it did not contain a 
control group and it was not blinded, weakening the study results.  
 
Lamiki et al (2010) conducted a prospective, randomised, open-labelled study in 46 patients 
suffering from SUDD (Table 2.2). The symptoms assessed were constipation, diarrhoea and 
abdominal pain.  All patients were asymptomatic at the start and no dietary advice was given.  
The patients were advised to  take  10 ml  of  a  symbiotic  mixture  three  times  a  day.  A  30 ml  
symbiotic mixture contained: Lactobacillus acidophilus 145 (3.75	 by	 105) Lactobacillus 
helveticus ATC 15009 (3.9 by 108), Bifidobacterium spp. 420 (1.485 by 109) mixed with enriched 
phytoextracts10 (27.3g) over a six-month period. The study showed that the symbiotic mixture 
was effective in preventing the recurrence of SUDD in 68.0% (31/46 patients), reducing 
constipation and having a positive effect on the gut flora (Lamiki et al 2009).  There was no 
control group in the study design, making it difficult to determine whether the probiotic or the 
phytoextract created the positive effect.  The difference in the reduction of symptoms between the 
balsalazide and probiotic study (Tursi et al 2007), versus the probiotic and phytoextract study 
(Lamiki et al 2010) was marginal, 73.3% (11/15) and 68% (31/46) respectively.  
 
Sheth and Floch (2009) reviewed 4 studies (Frič & Zavoral 2003; Tursi et al 2006; Tursi et al 
2007; Giaccarci, Tronci, Falconieri & Ferrieri 199311), to determine the efficacy of probiotic use 
in the treatment of DD.  They concluded that as the studies were small, and combined with other 
therapies, the impact of probiotics in the treatment of SUDD was unclear, however, probiotics 
may be an effective management tool to help reduce diverticular inflammation.  Sheth & Floch 
(2009) recommended that RCT were needed before probiotics could be recommended in the 
treatment of SUDD. 
                                                
10 Consisted of a prebiotic phytoextract mix of vaccinium myrtillus, ribes nigrum, urtica dioica, taraxacum officinalis leaves and  
    roots, equinacea purpurea leaves and roots, daucus carota in the amounts of 82g/100 ml. 
 
11 The original study by Giaccarci et al (1993) could not be obtained and has been cited (Sheth & Floch 2009).  The other three 





A more comprehensive and sophisticated study design was presented by Lahner, Esposito, Zullo, 
Hassan, Cannaviello, Paolo, Pallotta, Garbagna, Grossi & Annibale in 2012.  In a randomised, 
controlled, parallel-group study, the effects of a HFD and a symbiotic containing Lactobacillus 
paracasei B21060 were assessed in 44 SUDD patients over a six-month period (Table 2.2).  
Group A (24/44) received the HFD (>30 g per day) and 1 sachet of Flortec©.  This symbiotic 
preparation consisted of 5 by 109 Lactobacillus paracasei B21060, 500mg glutamine, 700 mg 
xylooligosaccharides12 (XOS) and 1243 mg arabinogalactone13.  Group B (21/44) was only 
treated with the HFD (>30 g per day).  Dietary counselling and an information sheet were issued 
regarding the dietary fiber contents of foods including vegetables, fruits and cereals.  During the 
seven days before the study took place, patients had to record their daily fiber intake.  A 
maximum of four points was given: one point for the intake of vegetables, a point for the intake 
of whole grain cereals at lunch, another point for whole grain cereals at dinner and a point for an 
intake of fruit.  To verify compliance to the HFD a clinical interview was done at entry and at 
three months and six months.  Abdominal pain lasting less than 24 hours, abdominal pain lasting 
greater than 24 hours and abdominal bloating were also measured at baseline and at three months 
and at six months.   
 
Statistically, there was no difference between dietary fiber intake score in both of the groups 
(group A: 13.3 ± 7.3 vs group B: 16.0 ± 9.1) at the end of the six-month study.  A significant 
reduction (30%) in abdominal bloating was noted in the symbiotic treatment group A (p=0.005) 
and no significant changes were observed in group B (p=0.11).  Group A (75%) showed a 
significant reduction in abdominal pain lasting less than 24 hours (p<0.001) as well as group B 
who presented with a 52.4% reduction (p=0.001).  Group A (55%) had a higher reduction in 
abdominal pain lasting greater than 24 hours (p<0.001) compared to group B (23.8%) (p=0.03), 
giving an indication that a HFD in addition to a symbiotic preparation is more beneficial in 
reducing symptoms in SUDD patients.  In group B (HFD), the onset of new abdominal symptoms 
had developed in three patients, one had prolonged abdominal pain and the other two suffered 
from abdominal bloating compared to the Flortec© group, who had not developed any new 
symptoms.  Lahner et al (2012) concluded that a HFD was effective in relieving abdominal pain 
                                                
12 Xylo-oligosaccharides is a mixture of oligosaccharides and xylose residues which acts as a prebiotic in the colon (Aachary  
    & Prapulla 2010). 
 




in most patients and combining a HFD with a symbiotic preparation such as Flortec©, showed a 
significant reduction in abdominal bloating and abdominal pain in SUDD patients.  Once again, 
the use of a synergist complex versus the use of probiotics alone had not been assessed in the 
Lahner et al (2012) study, raising the question as to which component in the study (probiotic, 
glutamine, XOS or arabinogalactone) actually made the overall difference. 
 
Tursi, Brandimarte, Elisei, Picchio, Forti, Pianese, Rodino, D’Amico, Sacca, Portincasa, 
Capezzuto, Lattanzio, Spadaccini, Fiorella, Polimeni, Polimeni, Stoppino, V., Stoppino, G., 
Giorgetti, Aiello & Danese (2013) conducted a multi-center, randomised, parallel-group, double-
dummy, double-blind, placebo-controlled study based on the pilot study by Tursi et al (2006) 
(Table 2.2).  Tursi et al (2013) replicated the previous study using the same dosage of mesalazine 
with or without the same amount of Lactobacillus casei subsp. DG, given over ten days per 
month rather than fifteen days per month.  The study also included a placebo arm (Tursi et al 
2013).  A total of 210 SUDD patients were randomised to four groups (Table 2.2).  Group M was 
prescribed 1.6 g of active mesalazine per day and a probiotic placebo.  Group L was given 
mesalazine placebo and active probiotic i.e. Lactobacillus casei subsp. DG (24 by 109 lyophilized 
bacteria).   Group LM was prescribed 1.6 g of active mesalazine per day and the active probiotic 
(24 by 109 lyophilized bacteria) and lastly, the P group was asked to take mesalazine placebo and 
probiotic placebo.  Each group took their allocated treatment for ten days per month over the 
twelve-month period.  No dietary interventions were implemented during the study. Remission of 
previous SUDD episodes14 was the primary endpoint of the study.  
 
None of LM group experienced recurrence of SUDD symptoms although recurrence occurred in 
7 patients in the M group (13.7%; 7/51), 8 patients in the L group (14.5%; 8/55), and lastly 23 
patients in the P group (46.0%; 23/50) (LM group versus M group, P=0.015; LM group versus L 
group, P=0.011; LM group versus P group, P=0.000).  Recurrence of diverticulitis occurred in 
12.0% (6/50) of the P group and in only 1.8% (1/55) of the L Group (P=0.003).  The other two 
groups (LM and M) did not experience a recurrence of diverticulitis.  Tursi et al (2013) 
concluded that taking a probiotic or mesalazine alone, or in combination is significantly better 
                                                
14 Defined by Tursi et al. 2013 as “the absence of recurring abdominal pain scored ≥ 5 for at least 24 consecutive hours and   





than a placebo in preventing the occurrence of diverticulitis in SUDD patients.  The results from 
Tursi et al (2013) were very similar to Tursi et al (2006) though a placebo group was added to 
Tursi et al (2013) to strengthen the results and allowed for better comparison between the groups.   
The use of the probiotic and vitamin cocktail mix in Tursi et al (2006) study and the use of the 
probiotic alone in Tursi et al (2013) study, seemed to provide evidence that the probiotics was in 
fact, the main driver for reducing the recurrence of SUDD symptoms and not the vitamin 
cocktail.  
 
The review by Guslandi (2013)15 emphasized that not all probiotics are alike and that the type of 
probiotic needs to be tested separately to understand the suitability of probiotic use in SUDD 
patients.  Although, the conclusion of the 201616 systematic review by Lahner, Bellisario, 
Hassan, Zullo, Esposito & Annibale stated that the paucity of high-quality data for the use of 
probiotics in the treatment of SUDD do not allow firm recommendations to be made, single 
controlled studies seemed to show an improvement in the reduction of symptoms (Lahner et al 
2016).   
 
As probiotics may potentially be beneficial in the treatment of SUDD and prebiotics enhance the 
growth and survival of probiotics, prebiotics may play a role in treatment of SUDD (Anderson et 
al 2009; Lahner et al 2016). 
 
2.8 PREBIOTIC EFFECT ON GUT MICROBIOTA  
 
 
Prebiotics are non-digestible, fermentable food ingredients or substances that are able to stimulate 
the growth and/or activity of beneficial microbiota in the colon, thereby providing a healthy 
environment for the host (Slavin 2013).  Slavin (2013) stated that “although all prebiotics are 
fiber, not all fiber is prebiotic”.  Prebiotics and probiotics are also known as “functional foods” 
                                                
15 Which included most of the studies discussed in this literature review (Frič & Zavoral 2003; Tursi et al. 2006; Tursi et al.  
    2007; Lamiki et al. 2009; Lahner et al. 2012; Tursi et al. 2013) except for Stollman, Mogowan, Shanahan & Quigley’s     
   (2013) study.   
 
16 Which included most of the studies discussed in this literature review (Frič & Zavoral 2003;  Tursi et al. 2006;  Tursi et al.  
    2007; Lamiki et al. 2010; Lahner et al. 2012; Tursi et al. 2013) except for the following that were unobtainable: Giaccarci,  
    Tronci, Falconieri & Ferrieri (1993); Tursi, Brandimarte, Giorgetti & Elisei (2005); Tursi, Brandimarte, Giorgetti & Elisei  





that when administered, create a specific result, exert a metabolic effect or have an ability to 
change the host’s metabolism (Floch & Hong-Curtiss 2002). 
 
Common prebiotics used to initiate microbiota growth, mainly of Bifidobacteria and less often 
Lactobacillus (Slavin 2013), include soluble fibers such as inulin, GOS, FOS, wheat dextrin, 
acacia gum and psyllium (ispaghula) (Slavin 2013; Elisei & Tursi 2016).  Prebiotics, such as 
inulin and FOS, naturally occur in certain foods such as soybeans, leeks, chicory, oats, onion, 
artichokes, wheat, bananas, asparagus and garlic (Ten Bruggencate, Bovee-Oudenhoven, Lettink-
Wissink, Katan & van der Meer 2006; Slavin 2013).  Some insoluble fibers (wheat bran, whole 
grain corn) are also fermented to a small degree in the colon and therefore may have an effect on 
SCFA production, thereby acting as a prebiotic (Aldoori et al 1998).  Dietary fiber and prebiotics 
are able to both preserve the natural microflora and may enhance probiotic use (Floch & Hong-
Curtiss 2002). 
 
Crowe et al (2014) and Lamiki et al (2010) discussed the ability to manipulate prebiotics gut 
flora in a way that may play an important role in reducing or improving SUDD, and overall DD.  
The review by Park & Floch (2007) stated that there were no significant studies investigating the 
use of prebiotics in DD, although they mentioned that certain studies (Painter 1972, Findlay17 et 
al 1974 and Taylor & Duthie 1976), supported the use of dietary fiber (bran tablets, unprocessed 
bran, high fiber diet) in reducing symptoms in symptomatic DD.  The role of dietary fiber in 
SUDD has been reviewed earlier.  In summary, Brodribb and Humphreys (1976) found that  a 
high wheat bran intake showed a reduction in symptoms in DD patients (Table 2.1).  Ünlü et al 
(2012) and Elisei & Tursi (2016) reviews arrived at a conflicting conclusion regarding the use of 
a HFD.  Ünlü et al (2012) stated that the evidence for a HFD was weak whereas Elisei & Tursi 
(2016) concluded that even though there was inconsistent evidence, a HFD was still 
recommended.  Lahner et al (2012) found that a symbiotic preparation of prebiotics and 
probiotics (Flortec©) resulted in a good therapeutic response in SUDD patients.  The effects, 
however,  could be credited to either the prebiotic,  the probiotic or the HFD  (Lahner et al 2012).  
  
                                                
17 The following journal article was unobtainable:  Findlay, J.M., Mitchell, W.D., Smith, A.N., Anderson, A.J & Eastwood, M.A.     
    (1974).   Effects of unprocessed bran on colon function in normal subjects and in diverticular disease.   Lancet 1 (7849): 146 -    






Over two-thirds of the Westernized elderly population have DD (Guslandi 2013) and 
approximately 20% develop symptomatic DD (Elisei & Tursi 2016). The ICCG has 
recommended a HFD even though the level of good quality evidence presented in the literature 
was lacking and none provided the actual amount of fiber that constituted a HFD.  Supplementing 
with fiber was also controversial as only two Consensus Guidelines promoted their use while the 
others either found them to be controversial, or did not promote their use at all.   Some of the 
studies showed a reduction of symptoms when SUDD patients were fed bran fiber supplements 
and/or a HFD, however, most of the studies had a small sample size, many did not have a control 
group and most lacked level one evidence.  A few studies had noted that a small percentage of 
patients were unable to supplement with unprocessed bran as the bran caused more abdominal 
discomfort (Painter et al 1972; Brodribb & Humphreys 1976).  
 
Probiotics are important for gut homeostasis, reducing inflammation and preventing bacterial 
translocation.  The use of certain probiotic strains in SUDD such as Escherichia coli Nissle, L. 
acidophilus 145, L. helveticus ATC  15009,  Bifidobacterium spp. 420, L. casei subsp. DG, VSL 
#3 (Lactobacillus plantarum DSM 24730, Lactobacillus acidophilus DSM 24735, Lactobacillus 
paracasei DSM 24733, Lactobacillus delbrueckii subsp. bulgaricus DSM 24734, Bifidobacterium 
longum DSM 24736, Bifidobacterium breve DSM 24732, Bifidobacterium infantis DSM 24737, 
Streptococcus thermophiles DSM 24731) and Lactobacillus paracasei B21060, have shown 
promise in lowering abdominal symptoms with or without the help of other intervention 
strategies.  Most of the studies reviewed did however, use different probiotic strains, different 
intervention methods were used, small sample sizes had been implemented and high quality data 
was lacking.  
 
Prebiotics provide fuel for the microbiota yet there are no studies to recommend their use in 
SUDD.  Certain fibers may act as a prebiotic requiring further investigation into their use in 
SUDD.   The current confusion that resides around the use of a HFD in SUDD as well as 
prebiotic, probiotic and fiber supplementation requires further investigation in order to determine 




CHAPTER 3: METHODOLOGY 
 
3.1 TYPE OF STUDY 
 
The study was a quantitative, descriptive study.  All RDs who were currently treating or who had 
treated DD in SA at the time of the study were invited to complete a self- administered 
questionnaire. 
 
3.2 STUDY DESIGN 
 
Quantitative research is well suited to online questionnaire data collection, problem 
quantification, determining the effectiveness of treatment methods and allowing for statistical 
inferences (Sandelowski 2000; Neergaard, Olesen, Andersen, & Sondergaard 2009).  A self-
administered open and closed ended questionnaire was considered to be the best method to use as 
it was cost effective and enabled distribution to a larger sample size (Walonick 1993; 
Sandelowski 2000; Grimes & Schulz 2002).  Respondents are also familiar with questionnaires 
and are less likely to feel apprehensive when filling them out (Walonick 1993).  The limitations 
of using an open-ended questionnaire is that more time is required to interpret the questions and 
the researcher may subjectively interpret the results (Munn & Drever 1990).  Closed-ended 
questions, however, limit the response to the question outlined and can be suggestive, rather than 
allowing for a spontaneous response (Reja, Manfreda, Hlebec & Vehovar 2003).   
 
The advantage of the descriptive approach was that it allowed participants to state their beliefs 
and practices regarding nutritional intervention in DD.  The disadvantage, however, is that the 
data could be subjectively interpreted (Grimes & Schultz 2002).    
 
3.3 SAMPLE SELECETION AND STUDY POPULATION 
 
Non-probability snowball sampling was used in order to reach as many dietitians as possible.  
Technically there was no sample selection as the goal was to invite all RDs in SA who treated 




Health Professional Council of South Africa (HPCSA) has the largest data base of RDs in SA 
(3139 were registered at the time of the study), confidentiality laws prevented access to the 
database.  As the next largest data base was that of ADSA (1500), sampling was initiated with 
ADSA members.  As approximately 52% did not belong to ADSA, internet searches were 
conducted using the term “dietitian”.  Details were downloaded from internet sites such as the 
Discovery Vitality Wellness Nutrition dietitian list (Discovery Vitality Wellness Network 2016) 
and Medline pages. Questionnaires were handed out at ADSA meetings.  The sample size was 
then “snowballed” by encouraging each respondent to forward the study information and web 
link onto all dietitians on their contact lists.   
 
The study population included RDs practicing in SA who had treated DD or who were currently 
treating DD.  
 
3.4 DATA COLLECTION, INSTRUMENTS AND TECHNIQUES 
 
3.4.1 Research instrument and validation  
 
An open and closed-ended, self-administered questionnaire (Appendix A) was initially designed 
and tested in a pilot study and then modified based on the detailed input of the RDs treating DD.  
The questionnaire was designed to determine the treatment methods prescribed by RDs for 
patients with SUDD.  The questionnaire was not validated by an expert as there were no SA 
experts in the field of SUDD and no previous studies were available to base the questionnaire on.  
Each respondent on submission of the questionnaire was contacted by the candidate to clarify the 
answer.  
 
3.4.2 Pilot study 
 
A “Diverticular Letter” (Appendix B) was made available to all respondents and the letter 
contained a brief outline of the study, the researcher and supervisor details, a link to the 
questionnaire and an informed consent note.  An email containing the “Diverticular Letter” 




Natal (KZN) on the 23rd January 2014.  Participants were asked to fill in the questionnaire and 
then comment on the questions that had been presented to them and to highlight any problems, 
such as a lack of ambiguity.  Changes were made to the questionnaire according to the feedback 
given by the respondents and certain questions were expanded on to prevent misunderstanding, 
when interpreting the questions.  Registered dietitians who responded to the pilot study were 
known by name and were asked not to be part of the study.  Registered dietitians names were 
checked by the candidate to prevent the pilot study dietitians from being part of the study.    
 
3.4.3 Data collection 
 
Ethical clearance (HSS/0179/012) was obtained from the Humanities and Social Sciences 
Research Ethics Committee of the University of KwaZulu-Natal (UKZN) (Appendix C). 
 
Roberta Govender, the secretary for ADSA (Roberta@vdw.co.za), was contacted and asked if the 
ADSA newsletter could be used to invite participation in the study.  On the 8th April 2014, the 
ADSA newsletter contained the “Diverticular Letter” (Appendix B) with the link to the 
questionnaire (http://diveticulitis.weebly.com/).  The “Diverticular Letter” contained an informed 
consent statement.  The questionnaire, hosted by Weebly, was password protected (DIET) to 
ensure that only ADSA members filled this in.  Registered dieticians downloaded the 
questionnaire, completed it and then emailed the response either to the research supervisor, Dr 
Chara Biggs (biggsc@ukzn.ac.za) or the researcher (tanyamarch@telkomsa.net).  The researcher 
or supervisor reviewed the questionnaire immediately and any queries were immediately 
followed up via email, with the registered dietitian.  Once clarity was obtained, the questionnaire 
was allocated a study identity number and the original email deleted to ensure confidentiality.  
Respondents were then asked to forward the email onto all other dietitians that they knew, 
creating a sampling snowball effect. 
   
The initial DD letter that was sent out by ADSA in April 2014 had a poor response rate. Other 
websites then had to be considered (Discovery, Medline Pages) in order to obtain RDs details 
which allowed for the DD letter and questionnaire to be sent out.  In an effort to further increase 




(cath.day.rd@gmail.com), the ADSA communication representative was contacted on the 30th 
August 2015 in order to resend the newsletter to encourage participation. On the 1st September 
2015, the “Diverticular letter” and a link to the questionnaire was resent.   
 
In addition, the Discovery Vitality Wellness Nutrition dietitian list was obtained from the internet 
and each applicant was directly emailed the “Diverticular letter” (Appendix B) and the study 
questionnaire (Appendix A).  This was followed by two reminder emails.  The researcher phoned 
and sent emails to RDs who were listed on the Medline pages and ADSA website.  The 
researcher attended the ADSA KZN branch meeting in September 2015 and handed out 
questionnaires that were completed and collected at the end of the meeting.  For the ADSA 
Johannesburg branch meeting, questionnaires were couriered in August 2015, handed out to 
members and the completed questionnaires were couriered back to the researcher.  Again, all 
dietitians who responded were encouraged to email the link onto other dietetic colleagues to 
increase the sample size.  Although a few dietitians employed at Government hospitals completed 
the questionnaire, some declined as the questionnaire had not been approved by the Nutrition 
Directorate from the KZN Health Department. 
 
To further increase the sample size, a R1000 Yuppie Chef voucher (Appendix B) was offered as 
an incentive and was awarded at the end of the study.  Registered dietitians who were part of the 
study were allocated a number and a winner was randomly selected.  The winner was contacted 
and the prize was given to them. 
 
The period of data collection was from April 2014 to December 2015.   
 
3.5 VARIABLES INCLUDED IN THE STUDY, DATA CAPTURING AND ANALYSIS 
 
3.5.1 Data analysis 
 
All the data from the questionnaires were captured on two separate occasions into an excel 
program that was specifically designed by the statistician (Gill Hendry, 




which were then rectified.  The data was then analysed by the statistician using Statistical 
Package for the Social Sciences (SPSS), version 21.0 dissertation. 
 
Descriptive statistics including means and standard deviations were used to analyse the data and 
frequencies were represented in tables or graphs (Table 3.1).  A chi-square goodness-of-fit-test, a 
univariate test was used on a categorical variable to test whether any of the response options were 
selected significantly more or less often that the others.  Under the null hypothesis, it was 
assumed that all responses are equally selected when the data was analysed.  Chi-square test of 
independence was used on cross - tabulations to determine whether a significant relationship 
existed between the two variables represented in the cross-tabulation.  When conditions were not 
met, a Fisher’s exact test was used.  Trigger foods that were listed had been recoded so that 10 
were listed as most important and 1was listed as least important (out of 10 listings).  Therefore, 
the sum of the listing code gave a measure of importance of a specific item.  A table of these 
measures, ordered from most important to least important follows the individual frequency table 
outlined in chapter 4.  A p value of <0.05 was taken as statistically significant. 
 
Table 3.1:  Data analysis of objectives 
 
Objectives Variables used for the 
analyses 
Method of analysis  
To determine whether RDs 
practicing in SA agreed with the  
Current Consensus Guidelines. 
Questionnaire OR 
Current dietary approach 
Descriptive statistics and 
Chi-square 
goodness- of- fit- test. 
To determine whether RDs 
practicing in SA supplemented with  
fiber in the treatment of SUDD. 
Trigger foods Descriptive statistics, 
significance p<0.05 and a 
Fisher’s Exact Test. 
To determine whether RDs 
practicing in SA identified specific  
Fiber supplementation Descriptive statistics and 
Chi-square 






3.6       DATA QUALITY CONTROL  
 
3.6.1 Field tested  
 
Rigour in the research is required in quantitative research to obtain an accurate measurement of 
the reliability and validity (Heale & Twycross 2015).  The validity refers to the extent to which a 
quantitative study is accurately measured (Heale & Twycross 2015).  The quantitative descriptive 
questionnaire was found to be the best approach to validate the study as the questionnaire was 
designed to achieve the objectives and to accurately measure the response (Heale & Twycross 
2015).  The quantitative descriptive questionnaire was also used to determine the current 
performance of SA dietitians in the treatment of SUDD and correlates performance with the 
concurrent behaviour practices of dietitians (Heale & Twycross 2015).   The use of open-ended 
questions allowed the respondents to express themselves more freely compared to close-ended 
questions (Heale & Twycross 2015). 
 
The reliability of a study depicts the coherence of a measure in order to yield the same results, 
when the research has been repeated (Heale & Twycross 2015).  Initially, a pilot study was 
foods believed to trigger attacks in  
SUDD. 
To determine whether RDs 
practicing in SA supplemented with 
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performed in 2014 to determine the efficacy of the questionnaire and was used to increase the 
reliability of the study.  During the study, dietitians were contacted to determine if there were any 
ambiguous questions that required further clarity, improving the outcome and reliability of the 
study.  The consistent measure used in the study was a questionnaire that included multiple 
choice questions, closed and open ended questions. The questionnaire was written in English 
(one of the official languages in SA) as most dietitians are taught dietetics at English speaking 
Universities in SA.  The data was captured twice in order to improve reliability of the study. 
 
3.6.2 Reduction of bias  
 
Using a self-administered questionnaire allowed the RDs to answer the questions without being 
swayed by an interviewer and neutral, open ended questions allowed the respondents to express 
their own thoughts and ideas, thereby reducing bias.  Contacting RDs to clarify their response in 
order to enable correct interpretation of the questionnaire also minimized a biased response.   
Simple and precise closed-ended questions were used in the questionnaire to decrease ambiguity 
and reduced biased feedback by RDs (Choi & Pak 2005).  
 
There was a selection bias as the questionnaire mainly reached those that had access to the 
internet and email although, there is a high probability that RDs would have had access to the 
internet and emails.  Another bias in the study is that it mainly focused on addressing RDs who 
were ADSA members attending ADSA meetings or who received the ADSA newsletter 
(Pannucci & Wilkins 2010).  Registered dietitians that did not have much interest in the field, 
may have answered the questionnaire briefly in order to obtain the prize, which could have 
introduced another bias towards the results of the study.   
 
3.7 ETHICAL CONSIDERATIONS 
 
The Humanities and Social Sciences Research Ethics committee of UKZN gave ethical clearance 





A covering letter (Appendix B) was sent to each respondent explaining the confidentiality of each 
completed questionnaire and that by completing the questionnaire, the respondents were giving 
the researcher consent to use it.  Registered dietitians were informed that the study was voluntary 
and they were able to withdraw at any time throughout the study period.  Registered dietitians 
were given the researchers and supervisors email address in case they had any queries or 
questions throughout the study period.  
 
In order to maintain confidentiality during the data management stage, the participants were 
allocated a study number.  The questionnaire was then destroyed by shredder machine and the 


















CHAPTER 4: RESULTS 
 
The results obtained from 155 RDs were analysed in order to determine the relevance of each 
question.  An overview of each question outlined in the study has been discussed in the following 
chapter. 
 
4.1 RESPONSE RATE 
 
A total of 155 RDs responded to the questionnaire.  At the time of the study, there were 3139 
RDs with the HPCSA, 47% (1500) of whom belonged to ADSA.  As the total number of RDs in 
SA who treated DD was unknown, it was not possible to estimate what proportion of the total 
treating DD was sampled.  Likewise, a response rate could not be calculated as the number who 
were invited to participate was unknown due to snowball sampling.  
 
4.2 PLACE OF EMPLOYEMENT 
 
Seventy five percent (116/155) worked in the private sector and 25.0% (39/155) in the 
government sector 
 
4.3 FREQUENCY OF TREATMENT 
 
A significant number (36.9%, 52/155) treated less than five patients per year (χ2 (3) = 19.369, 
p<0.0005).  A significant proportion (31.2%, 44/155) treated approximately two or more patients 
a month.  There was no significant difference for all treatment parameters between these two 






Figure 4.1:  Number of patients seen by dietitians per year 
 
4.4 RESPONSE TO THE CURRENT DIETARY GUIDELINES  
 
A significant majority (77,1%, 101/131) disagreed with the ICCG that promote an unrestricted 
HFD, compared to those (19.4%, 30/131) who agreed (χ2 (2) = 38.481, p<0.0005).  
 
4.5 DIETARY APPROACHES  
 
A significant difference (χ2 (2) = 166.805, p<0.0005) was found between the dietary approaches.  
The majority (57.7%, 86/149) believed that high soluble fiber plus insoluble fiber (wheat bran, 
bran flakes) with the avoidance of skins, pips, whole grains and nuts was the best approach used 
in-between acute attacks.  An additional 28.9% (43/149) supported this approach but supported 
the removal of insoluble fiber.  Only 7.3% (11/149) recommended a high insoluble fiber diet with 
greater than 25g of fiber per day (Figure 4.2). 
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Figure 4.2:  The dietary approaches used by registered dietitians 
 
4.6 FIBER SUPPLEMENTS 
 
A significant number either prescribed soluble fiber (35.4%, 51/144) or did not prescribe fiber 
supplements (53.5%, 77/144) (χ2 (3) = 97.889, p<0.0005).  A blend of fiber was recommended by 
9.0% (13/144) and 2.1% (3/144) prescribed insoluble fiber.  The fiber that was prescribed the 
most was psyllium husk (19.4%, 28/144), oat bran (16.7%, 24/144), Benefiber (wheat dextrin) 
(11.8%, 17/144) and Movicol18 (polyethylene glycol) (3.5%, 5/144) (Appendix D) (Figure 4.3).   
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Figure 4.3: Prescription of fiber supplementation 
 
4.7 TRIGGER FOODS 
 
A significant proportion of RDs (79.3%, 119/150) identified foods they believed provoked 
attacks of diverticulitis (p<0.0005), compared to 20.7% (31/150) who did not support the concept 
of trigger foods.  The foods most frequently identified as provoking attacks and having a high 
level of importance included seeds, nuts, pips, wheat, gas forming vegetables, fried/fatty foods, 
popcorn and fruit (Figure 4.4).  Legumes are classified as a seed and include beans, lentils, peas 
and peanuts.  The seed (legumes) heading in Figure 4.4 was required to differentiate legume 
based seeds from other seeds such as sesame seeds, pumpkin seeds, flax seeds, sunflower seeds 
and poppy seeds.  
 
 




















Figure 4.4:  Commonly identified trigger foods and the level of importance 
 
 

























4.8 USE OF PREBIOTICS AND PROBIOTICS 
 
The results obtained from 155 RDs were analysed in order to determine the relevance of each 





Approximately half (51.3%, 79/154) believed that prebiotics were beneficial in the treatment of 




Figure 4.5:  The percentage who found prebiotics beneficial 
 
Although the majority (70.6%, 108/153) believed that probiotics were beneficial in the treatment 
of DD (χ2 (2) = 103.804, p<0.0005), a quarter (24.2%, 37/153) were unsure of their potential role 





























Over half routinely prescribed probiotic supplements (55.3%, 84/152) and 18.4% (28/152) 
recommended using a combination of both prebiotic and probiotics (symbiotics), giving a total of 
73.7% (112/152) of RDS using probiotics or both (Figure 4.7).  Only 1.3% (2/152) prescribed 
prebiotics and 25.0% (38/152) prescribed neither (Figure 4.7).  A few respondents stated they did 
not prescribe prebiotics when in fact, it was in the supplement they prescribed and one other was 

























Figure 4.7:  Prescription of probiotics and prebiotics 
 
There was a significant relationship between opinions on the beliefs of probiotic use and the 
prescription of probiotic supplements (Fisher’s = 35.998, p<0.0005).  A significant number of 
those who saw the benefit of probiotics prescribed them; a significant number who did not see 
their benefit prescribed neither pre- nor probiotics. For those who were not sure of their benefit, a 
significant number prescribed neither. 
 
There was a significant relationship between opinions on the benefit of prebiotics and the 
prescription of prebiotic supplements (Fisher’s = 26.800, p<0.0005).  A number of RDs (26.9%, 
41/152) who claimed they only promoted probiotics and not prebiotics, did promote fiber 
supplements that were actually prebiotics.  Out of 25.0% (38/152) that claimed to prescribe 


















The two RDs who routinely prescribed prebiotics (Figure 4.7) recommended FOS.  Those that 
prescribed both, recommended prebiotics such as oat bran (2.6%, 4/152), inulin (2.0%, 3/152), 
FOS (2.0%, 3/152) and psyllium husks (1.3%, 2/152) while others prescribed a symbiotic 
preparation that was found in Probiflora Intensive Care 9, Ultra Flora Synergy and the Real 
Thing Pro-Probiotics (Appendix E).   
 
The most commonly prescribed bacteria found in the probiotic supplements were Lactobacillus 
acidophilus (22%, 34/155), Bifidobacterium lactis (21%, 32/155) and   Lactobacillus plantarum 

























The most common probiotics prescribed were, the Probiflora range (22.3%, 34/152), Metagenics 
(21.1%, 32/152), LP299V (11.1%, 17/152), Reuterina (8.6%, 13/152), Gastrochoice (7.2%, 
11/152) and VSL#3 (6.7%, 10/152) (Appendix E). Some RDs supplemented with two or three 
supplements in combination.  The probiotic strains of the main probiotic species prescribed are 
found in Table 4.1. The probiotic strains that were mentioned by the manufacturers were 
included. 
 
Table 4.1: The amount and type of probiotics prescribed 
 
Probiotic: 
Genus and Specie 
Probiotic Strains 
Lactobacillus acidophilus  
Lactobacillus acidophilus NCFM®  
Lactobacillus acidophilus HA-122 
Lactobacillus acidophilus DSM 24735 
Bifidobacterium lactis 
Bifidobacterium lactis HN019 
Bifidobacterium lactis Bi-0  
Bifidobacterium lactis Bl-04 
Lactobacillus plantarum  
Lactobacillus plantarum 299v  
Lactobacillus plantarum Lp-155 
Lactobacillus plantarum HA-119 
Lactobacillus plantarum DSM 24730 
Bifidobacterium longum 
Bifidobacterium longum Bl-05,  
Bifidobacterium longum HA-135 
Bifidobacterium longum DSM 24736 
Lactobacillus casei 
Lactobacillus casei Lc-11 
 
Bifidobacterium bifidum  
Streptococcus thermophiles  
Streptococcus thermophiles St-21 
Streptococcus thermophiles HA-132 
Streptococcus thermophiles DSM 24731 
Lactobacillus rhamnosous 
Lactobacillus rhamnosous HNO19 
Lactobacillus rhamnosous HNOO1 
Lactobacillus rhamnosous GG 
Lactobacillus rhamnosous BHA-114  





Symbiotics were prescribed by 29.7% (46/155) and a quarter (25.2%, (39/155) recommended a 
symbiotic that contained the prebiotic FOS.  These included Solal Probiotic Maximum, 
Probiflora 4, Probiflora 9, Probiflora Colonease, Biogen Probimax 4 Strain, Foodstate 11 Strain 
and Green Vibrance Health.  Two symbiotics, the Real Thing-Pro-probiotic and Nativa digestive  
(1.9%, 3/155), contained inulin and  oligofructose which was also found in the Real Thing Pro-
probiotic (1.3%, 2/155).  A symbiotic preparation that consisted of ispaghula husks was 
Probiflora Colonease (1.3%, 2/155).  
 
4.9 ADDITIONAL SUPPLEMENTS 
 
Omega 3 fish oils (14.8%, 23/155), L- glutamine (10.0%, 15/155) and multi–vitamin and mineral 
(7.1%, 11/155) containing products were the three additional supplements mainly prescribed.  
Digestive enzymes (2.6%, 4/155) and herbal extracts such as Iberogast19 (1.9%, 3/155) were 
prescribed by the minority.  Gastrochoice probiotics and Gastrochoice IBS were two of the 
probiotic supplements containing L-glutamine and digestive enzymes. 
 
4.10 LIFESTYLE RECOMMENDATIONS 
 
Nearly one third of participants (29.0%, 45/155) believed that the fluid intake should be 
increased.  Lifestyle changes included avoiding alcohol (17.7%, 12/155), encouraging healthy 
eating and exercise (9.0%, 14/155), regular and balanced meals (6.5%, 10/155), an individualised 
approach (5.8%, 9/155), keeping a food diary (3.9%, 6/155%), using the FODMAP diet (2.6%, 
4/155) and chewing properly (1.3%, 2/155). 
 
An individualised approach was mentioned throughout the study.  In the restriction of insoluble 
fiber, a few (11.0%, 17/155) believed a treatment approach should be individualised for each 
patient.  An individualised approach was advised by 17% (26/155) of the RDs when treating 
patients and treatment outcome also specified an individual approach.  
 
 
                                                
19 Plant-derived extract supplement composed of Iberis amara, Angelica, Chamomile, Caraway Fruit, St. Mary's Thistle,  Lemon Balm Leaves,    




4.11 TREATMENT OUTCOME 
 
The majority (73.6%, 109/148) felt that patients responded well with significant improvement in 
symptoms and had a decreased relapse rate (2 (2) = 192.054, p<0.0005) while 1.4% (2/148) 
believed that the diet did not work (Figure 4.9).   
 
 
Figure 4.9: Response of patients to the dietary approach 
 
Many respondents who chose “other” stated that patients did not come back for follow-up, 
leaving them unable to determine the success of the dietary approach they recommended.  Others 
stressed the importance of the response being individualised. 
 
Responded well to the diet
Responded well though found 
diet restrictive









4.12 SUMMARY  
 
A significant proportion (77.1%) of RDs disagreed with the ICCG and over half (53.5%) did not 
supplement with fiber supplements, whereas 35.4% prescribed soluble fiber supplements.  Over 
two thirds (79.3%) of RDs identified trigger foods that were believed to provoke DD attacks.  
The common trigger foods mentioned were seeds, nuts, pips, wheat, gas forming vegetables, 
fried/fatty foods, popcorn and fruits.  Prebiotics and probiotics were both found to be beneficial, 
although only 25.0% of RDs prescribed prebiotic and 55.3% recommended probiotics.  Different 
probiotic strains and species were noted in the study, the two most commonly prescribed 
probiotics were Lactobacillus and Bifidobacteria.  Additional supplements such as omega-3 fish 
oil, L-glutamine, multi-vitamin and mineral, digestive enzymes and Iberogast were advised by 
RDs.  Many (73.6%) RDs believed that their approach was successful in improving patient’s 







CHAPTER 5: DISCUSSION 
 
The ICCG have recommended the inclusion of a HFD in all patients with SUDD.  Reviewing the 
literature, assessing the current study’s findings and looking at anecdotal evidence, may help 
provide a clearer understanding of how to manage and treat SUDD. 
 
5.1 SECTOR OF EMPLOYMENT 
 
Out of the 155 RDs that responded to the questionnaire, a significant proportion (75%) worked in 
the private sector.  Petruzziello et al (2006) mentioned that urbanization and a Westernized diet 
have been linked to an increased prevalence of DD, which may explain why a greater number of 
the private sector dietitians responded as they may have been more likely to treat DD.  An 
additional consideration is that those that work for the government sector are less likely to treat 
DD as the Millennium Criteria Goals (MCG) outlined by the South African Department of Health 
(SA DoH) do not address DD (Department of Health, Republic of South Africa 2014).  The SA 
DoH focuses on the treatment of human immunodeficiency disease (HIV) and acquired 
immunodeficiency syndrome (AIDS), tuberculosis (TB) as well as child and maternal mortality 
(Department of Health, Republic of South Africa 2014).   
 
5.1.1 Frequency of treatment 
 
Although there was a vast difference in their exposure to DD20, those with the greater experience 
did not treat significantly differently to those with the least experience, regardless of the 
treatment parameter.  
 
5.2 DIETARY APPROACHES IMPLEMENTED VERSUS CONSENSUS GUIDELINES 
 
The term “high fiber diet” has been used very loosely in most of the ICCG, as it does not dictate 
the amount of soluble versus insoluble fiber that should be prescribed in SUDD.  A systematic 
review by Ünlü et al (2012) showed that there is inconsistent evidence to state whether a HFD 
                                                




should be used in the treatment of SUDD.  Yet the ICCG still recommend a high HFD in DD and 
in SUDD patients.    
 
The ICCG for DD state that patients should be encouraged to eat a HFD including insoluble 
fibers such as nuts, seeds and popcorn.  Most RDs (85.6%) recommended varying degrees of 
insoluble fiber restriction.  Over half (57.7%) promoted the avoidance of skins, pips, whole 
grains and nuts, although the inclusion of both soluble and insoluble fiber (including wheat bran 
and bran flakes) was promoted.  An additional third of the RDs (28.9%) supported this approach 
but recommended the removal of insoluble fiber.  Very few RDs (7.3%) recommended greater 
than 18 to >25 g of insoluble fiber per day as recommended by the consensus statements (Leahy 
et al 1985; Crow et al 2014; Cuomo et al 2014; Boynton & Floch 2013; National Health Service 
2015; United States Department of Health and Human Services and United States Department of 
Agriculture 2015; Stellenbosch University 2016).  Contrary to the ICCG, most RDs therefore 
believed that insoluble fiber in a variety of forms was responsible for provoking attacks.  
Dietitians in SA did not support the ICCG (WGO, AGA, Italian Consensus, Great Britain’s 
Royal College of Surgeons, National Health Services, Polish Consensus; Danish National 
Guidelines), advocating a HFD with no limitations on the type (insoluble versus soluble) of fiber 
(Murphy et al 2007; Andersen et al 2012; Royal College of Surgeons Advancing Surgical 
Standards 2014; Peery et al 2012; Pietrzak et al 2013; National Health Service 2015; Stollman et 
al 2015).  
  
Just under half prescribed fiber supplements (44.4%), with a very small percentage 
recommending the use of insoluble fiber (2.1%).  In the literature, the use of bran supplements 
(insoluble fiber) was shown to reduce symptoms in SUDD and yet none prescribed them. 
Approximately 57.5% believed that an insoluble fiber diet such as wheat bran and bran flakes 
would be the best dietary approach, contradicting their beliefs to their action. The ICCG for fiber 
supplementation are confusing, as two promoted (Andersen et al 2012; Pietrzak et al 2013) the 
use of fiber supplements without mentioning the type of fiber to supplement with, few stated that 
fiber supplementation is controversial (Cuomo et al 2014; Stollman et al 2015) and two others 
(Murphy et al 2007; Royal College of Surgeons Advancing Surgical Standards 2014) did not 




Only four RCT studies were reviewed by Ünlü et al (2012), as they met the criteria for obtaining 
a control group and each used different treatment methods i.e.: different doses and different types 
of fiber supplements (bran, ispaghula, methylcellulose).  All the studies had a small sample size 
which makes it difficult to demonstrate a significant effect in SUDD patients consuming high 
fiber supplements.  A recent review by Elisei and Tursi (2016) commented on the lack of data to 
support the role of fiber in the use of SUDD patients.  However, it was mentioned that a HFD is 
still recommended in SUDD.  Although Leahy et al (1985), Strate et al (2008) and Crowe et al 
(2011) prospective studies had been reviewed, Crow et al (2011) & Strate et al (2008) study did 
not look at abdominal symptoms and is questionable when assessing their results in SUDD 
(Elisei & Tursi 2016).   
 
Over a third prescribed soluble fiber (35.4%) primarily psyllium husk followed by oat bran and 
wheat dextrin. The dietitians did not mention the amount they prescribed.  Most of these fibers 
have a prebiotic effect in the gut.  There seems to be a lack of general knowledge surrounding 
prebiotics as some dietitians prescribed soluble fiber supplements that act as prebiotics, while 
denying that they supplemented with prebiotics.   
 
Three of the studies showed that between 12g to 24g of bran supplementation may have a 
beneficial effect on reducing abdominal symptoms (Painter et al 1972; Brodribb & Humphreys 
1976; Taylor & Duthie 1976).  In the Painter et al (1972) and Brodribb & Humphreys (1976) 
studies, it was found that a small percentage of patients could not tolerate the supplemented 
unprocessed bran as it caused symptoms such as constipation, abdominal discomfort or nausea.  
In the Taylor & Duthie (1976) study, the authors found that a HFD plus supplementing the diet 
with unprocessed bran where possible (the amount of fiber consumed per day was not noted in 
the study), had a much lower reduction in eliminating symptoms (20.0%) compared to patients 
supplementing with their normal diet and bran tablets (60.0%).  This implies that a HFD may be 
more likely to contain certain trigger foods and high roughage food, reducing symptom 
improvement, whereas increasing fiber by using simple bran tablets that have been refined into 





Trigger foods were not supported by any of the ICCG (Andersen et al 2012; Pietrzak et al 2013; 
Royal College of Surgeons Advancing Surgical Standards 2014; Cuomo et al 2014; Stollman et 
al 2015).  Despite the limited evidence to support the inclusion or exclusion of trigger foods 
(Strate et al 2008; Tarleton & DiBaise 2011), the majority (79.3%) believed that specific foods 
triggered attacks and identified seeds, nuts, pips, wheat, gas forming vegetables, fried/fatty foods, 
popcorn and fruits as being common problematic foods which is in accordance with the historical 
approach (Tarleton & DiBaise 2011; Peery & Sandler 2013).  
 
Two dietitians from the current study stated that “from my experience and from working with 
three gastroenterologists, we have found the above items (insoluble fiber, pips, gas forming fruits 
and vegetables) significantly worsens symptoms and episodes of relapse” and that “surgeon says 
pips get stuck in diverticula”.   Interestingly, this has been supported by comments posted on the 
internet.  A number of patient reviews posted on the NHS website criticized the high fiber 
recommendations and stated that abdominal symptoms worsened (National Health Service 2015).  
Some seemed to be sensitive to foods such as whole meal bread, nuts, fruit and by generally 
following a high fiber diet (National Health Service 2015).  
 
Thompson (2016), a medical doctor posted a remark by a diverticular patient: “ I have had 
diverticula this condition for twenty-five years. On several occasions the ingestion of nuts and 
seeds and even shredded coconuts has caused the most acute repeated attacks of diverticulitis, 
marked with acute pain on the left side, bowel movement distress, and a fever. When nuts, seeds, 
and offending foods were eliminated from my diet I no longer suffered the diverticulitis symptoms 
described above – except on one or two occasions when due to careless lapses in such dietary 
precautions, (such as eating an unidentified mixed dish in a darkly-lit restaurant) the attack 
recurred.  Moreover, a sibling with the same condition experienced precisely the same symptoms 
after eating seeds and nuts. Only a diet that scrupulously avoids these foods in her case and in 
mine has prevented subsequent attacks of this kind. I would appreciate some clarification 
regarding the role of diet in this syndrome with special reference to the question of seeds, nuts, 





Other patient responses to dietary intervention for SUDD were obtained from patient support 
website groups: 
 
”Avoiding any root vegetables (these cause wind and irritate the pockets) keeps me mainly flare 
free, also be careful with beef, pork and lamb” (Anonymous 2016). 
 
“I cannot eat seeds or any kind, I have a flare up right now caused I believe by fresh figs. 
Strawberries, blackberries and raspberries are also out” (MedicineNet.com 2016a). 
 
“I cannot eat nuts” (MedicineNet.com 2016b). 
 
“My surgeon had mentioned that it was ok to eat a wide variety of things, including those with 
seeds, but I found out the hard way that was NOT the case for me. I had something with sesame 
seeds, for example, and I had one of the worst attacks I ever had” (Topix 2016). 
 
“There’s a definite connection for him between it (developing diverticulitis) and small seeds.  
Like poppy or sesame seeds on bread, or certain ones in fruit.  Can’t have them” 
(HealingWell.com 2008). 
 
Many of the ICCG rely heavily on the prospective cohort study by Strate et al (2008), which 
concluded that the consumption of nuts, corn, popcorn and seeds does not provoke diverticular 
complications, are not associated with SUDD and may be protective rather than harmful.  The 
study by Strate et al (2008) did not focus on men greater than 60 years of age and current studies 
show that DD increases considerably in people over the age of 60 years.  Likewise, symptoms 
such as abdominal pain, abdominal discomfort and constipation were not monitored, providing 
limited evidence on the effects that nuts, popcorn and corn may have on the gut.  
 
It is possible that dietitians treat those SUDD patients intolerant to bran or a HFD.  This would 
explain the overwhelming belief in trigger foods and the need to restrict specific types of fiber by 
dietitians.  Salzman & Lillie (2005) mentioned that patients with SUDD usually find that eating 




participants in the study, may be more beneficial than a “generic approach’ as it is possible that a 
sub section of SUDD sufferers are intolerant to the HFD and react to specific trigger foods, a 
possibility that the guidelines should not ignore.  Two approaches could be offered – a HFD 
could be the first line of treatment followed by the removal of insoluble fiber including nuts, 
seeds and popcorn as the second line of treatment, if the HFD worsens the symptoms.  The 
exclusion diet could then be slowly liberated so as to identify the trigger foods.  Bran 
supplementation may be included in insensitive individuals although an individualised approach 
is required.  
 
5.3 USE OF PREBIOTICS AND PROBIOTICS 
 
More confidence was placed in supplementation with probiotics rather than prebiotics as a greater 
number of DD studies have investigated the use of probiotics in SUDD.   
 
5.3.1 Prebiotic use 
 
Although there are no studies showing the efficacy of prebiotic use in DD (Park & Floch 2007; 
Cabré 2011), over half of the participants believed that prebiotics were beneficial.  The minority 
(1.3%), however, prescribed prebiotics (FOS) which showed that their prescription did not match 
up to their beliefs.  There were dietitians who claimed that they did not supplement, yet 
prescribed probiotic supplements (Probiflora and Gastrochoice) which contained FOS. The 
beliefs of some did not match up to their prescription such as those who only recommended 
probiotic use (24.0%), even though they also prescribed fiber supplements which are known to be 
a prebiotic.  The lack of general knowledge surrounding prebiotic use may be a result of limited 
research to support its use in SUDD and that probiotics tend to be more widely investigated, 
allowing more emphasis on probiotic use.   
 
The main reason for prescribing FOS was to increase the Bifidobacteria population and to a 
lesser extent, Lactobacilli.  Both assist in lowering the colonic pH thereby creating an 
environment in which pathogenic bacteria e.g. Clostridia find difficult to survive (Floch & Hong-




increases phagocytosis and help restore the gut flora after antibiotic use (Floch & Hong-Curtiss 
2002).  The use of FOS may then be beneficial and could potentially be an appropriate choice, 
even though there was no current research to support its use in SUDD.  
 
5.3.2 Probiotic use 
 
Lactobacillus, Bifidobacterium, Escherichia and Streptococcus have been assessed in the 
treatment of DD (Frič & Zavoral 2003; Tursi et al 2006; Tursi et al 2007; Lamiki et al 2010; 
Lahner et al 2012).   Over half of the probiotics prescribed in the current study contained a 
variety of species and strains of Lactobacillus (53.0%), Bifidobacterium (39.0%) and 
Streptococcus (8%).   Most of the species and strains promoted by the dietitians were not the 
probiotics which had been investigated in the literature.  
 
Probiotic species have different properties and may be strain-specific in their action (Boyle, 
Robins-Browne & Tang 2006).  It is important not to generalize the effect one probiotic strain 
may have compared to another, even when the species are the same (Boyle et al 2006).   It is 
important therefore to consider the strain-specific probiotic and whether the use was appropriate 
in SUDD (Boyle et al 2006; Tursi 2010).   It cannot be assumed that the same probiotic genus or 
specie will have the same effect in the gut and using strain-specific probiotics requires a thorough 
evaluation of safety before marketing the probiotic (Boyle et al 2006).   
 
Strain specific probiotics used in the treatment of SUDD resulted in a positive reduction in 
symptom response such as abdominal discomfort, abdominal pain, constipation and abdominal 
bloating (Frič & Zavoral 2003; Tursi et al 2006; Tursi et al 2007; Lamiki et al 2010; Lahner et al 
2012).  These included Escherichia coli Nissle, L. acidophilus 145, L. helveticus ATC  15009,  
Bifidobacterium spp. 420, L. casei subsp. DG, VSL #3 (Lactobacillus plantarum DSM 24730, 
Lactobacillus acidophilus DSM 24735, Lactobacillus paracasei DSM 24733, Lactobacillus 
delbrueckii subsp. bulgaricus DSM 24734, Bifidobacterium longum DSM 24736, Bifidobacterium 
breve DSM 24732, Bifidobacterium infantis DSM 24737, Streptococcus thermophiles DSM 
24731) and Lactobacillus paracasei B21060.  These probiotic strains were shown to be effective 




mesalazine or an antimicrobial.  Tursi et al (2007) demonstrated that VSL#3 was seen to cause a 
remission in abdominal symptoms by up to 60.0% over a twelve-month period (Tursi et al 2007). 
Lamiki et al (2010) also showed that 68.0% of SUDD patients were symptom-free within a six- 
month period when a probiotic mix, prebiotics and phytoextracts were used.   
 
Of those (73.8%) who prescribed probiotics, only a small minority (7.0%) recommended VSL#3 
(6%) and Vivomixx (1%), which contained the actual probiotic species and strains investigated in 
the treatment of SUDD (Tursi et al 2007; Lahner et al 2016).   Escherichia coli Nissle 1917 was 
also not prescribed by any of the dietitians.  Other probiotics prescribed contained the same 
probiotic genus but different species and strains that had not been researched.  For example 
Lactobacillus acidophilus was contained in probiotic supplements such as Gastrochoice, 
Probiflora Colon Ease, Real Thing Pro-Probiotic, Biogen Probimax 4 and Food State 11 Strain, 
although the strain was not mentioned.  The prescription of probiotics by most of the dietitians in 
the current study does not coincide with those strains researched in the treatment of SUDD 
(Sheth & Floch 2009; Limiki et al 2010).  The intention of the dietitians to supplement with a 
probiotic in SUDD patients was appropriate although their practice was not evidence-based.   
 
5.4 ADDITIONAL SUPPLEMENTATION 
 
There is no direct evidence to support the use of omega-3 fish oil (15%) and L-glutamine (10%) 
in SUDD, yet these supplements were recommended.  A review by Seamen (2002) mentioned 
that diverticulitis is an inflammatory disease and to reduce the chances of developing an 
inflammatory response in the body, omega-3 fish oil may help to reduce inflammation which in 
turn, may provide pain relief  (Barbalho, Goulart, Quesada, Bechara, & de Carvalho 2016).  
Many patients with DD suffer with low-level mucosal inflammation (Sheth, Longo & Floch 
2008) and may benefit from omega-3 fish oil supplementation.  Diets deficient in omega-3, 
antioxidants, phytochemicals, vegetables and fruit may induce a pro-inflammatory state and DD 
is inflammatory in nature (Seaman 2002).  Bouteloup-Demange, Claeyssens, Maillot, Lavoinne, 
Lerebours & Dechelotte (2000) discussed the benefits of glutamine supplementation on the gut 
barrier as glutamine is the major fuel for enterocytes in the intestinal mucosa.  Glutamine 




increased permeability of the gut, reduce disease activity and lower intestinal damage 
(Bouteloup-Demange et al 2000; Akobeng, Miller, Stanton, Elbadri & Thomas 2000).  However, 
there seems to be no research to support glutamine use in DD.  Glutamine has been shown to 
have certain prebiotic activities in the faecal flora of the human gut (Lahner et al. 2012).  Lahner 
et al (2012) investigated Flortec© which contained 500 mg of glutamine and demonstrated a 
significant reduction in symptoms but this may be attributed to a HFD as well as the inclusion of 
a prebiotic and probiotic.   
 
5.5 LIFESTYLE RECOMMENDATIONS   
 
At present, there is no supporting evidence to suggest lifestyle modifications for SUDD.  
Approximately a third (29%) recommended an increase in fluid intake.   Siegel & Di Palma 
(2005) did mention that constipation was a factor in SUDD and recommended a high fluid intake, 
in conjunction with an increased intake of fiber, was thought to help reduce constipation.  The 
RCS commissioning guide also promoted a higher fluid intake if fiber increased in DD (Royal 
College of Surgeons Advancing Surgical Standards 2014).  
 
Some participants (18%) recommended the avoidance of alcohol while others (9%) advocated 
increased exercise.  Interventions such as reducing alcohol consumption and regular exercise 
have been recommended in preventing the reoccurrence of diverticulitis (Wilkins et al 2013; 
Pisanu et al 2013).  However there seems to be conflicting opinions in the literature regarding the 
exclusion of alcohol (Aldoori, Giovannucci, Rimm, Wing, Trichopoulos & Willett 1995b; 
Wilkins et al 2013).  Wilkins et al (2013) advocated a reduction in the intake of alcohol whereas 
Aldoori et al (1995b) found no benefit in excluding it.  Regular exercise was found to be 
beneficial in the reducing the reoccurrence of SUDD according to Wilkins et al (2013) and 
Aldoori, Giovannucci, Rimm, Ascherio, Stampfer, Colditz, Wing, Trichopoulos, & Willett 
(1995a).  The prospective men’s study by Aldoori et al (1995a) showed an increased risk of 
SUDD in men with low activity levels and low fiber intake.  There is limited evidence to support 
the reduction or exclusion of alcohol in SUDD patients and regular exercise may be beneficial in 





5.6 TREATMENT OUTCOMES 
 
The dietitians who participated in the study strongly believed in the approach they were using as 
the majority (74%) felt their patient’s symptoms improved as there was a decreased relapse rate 
which is not in accordance with the ICCG.  However, dietitians may have been referred those 
patient’s in which the HFD had failed and therefore required further individualised assistance to 
improve their SUDD.    
 
5.7 SUMMARY  
  
The dietitians  who  participated  in  this  study  did  not  prescribe  the HFD recommended by the 
ICCG.  Many  prescribed  different  degrees  of  insoluble  fiber  restriction  including skins, pips,  
whole  grains  and  nuts,  while  wheat  bran  and  bran  flakes  were  promoted.   The participants  
believed  that  certain  trigger foods impacted SUDD and identified nuts, seeds, pips, gas forming  
vegetables, fried/fatty foods, popcorn and fruit as being the main trigger foods.  Soluble fiber was  
the most  prescribed  fiber  supplement  and a very small percentage advised insoluble fiber.  The  
use  of  bran  supplements  had  been  shown  in  the  literature  to be useful in SUDD, yet not one  
dietitian  prescribed  their  use.   Despite the lack of evidence,  the minority prescribed prebiotics.   
The  knowledge  surrounding  prebiotics  was  poor as those who supplemented with soluble fiber  
were   unaware   of   its   prebiotic   role   and   some  supplemented  unknowingly.   The majority  
prescribed  strains  of  probiotics  that  had not been researched in SUDD and very few prescribed  
the  probiotics  that  the  literature  had identified as having positive results in reducing abdominal  
symptoms  in  SUDD.   Few  supplemented  with either omega-3 fish oils or glutamine, neither of  
which  has  been  investigated  in  SUDD.   A  HFD with the inclusion of a high fluid intake, may  
reduce  constipation  in  SUDD.   The  recommendations  surrounding  a  decrease  in  alcohol  is  
conflicting  although  the  increased  exercise  recommended  by  some  may  be  beneficial.   An  
individualised  approach  was  promoted  and  the  majority believed that their treatment approach  
showed  a  significant  improvement  in  symptoms  and  relapse rate.  At the time of the write up,  
Universities were  unable  to  provide  an  indication  of the study material they used to teach DD.    









The purpose of this research was to examine dietary treatment methods used by SA dietitians 
when treating SUDD and to determine their beliefs regarding the international current dietary 
guidelines for SUDD, trigger foods, the use of a HFD, fiber supplements, prebiotics and 
probiotics.  Although the ICCG advocates a liberal unrestricted HFD for patients with SUDD and 
that nuts, seeds and popcorn do not appear to exacerbate DD symptoms.  There was conflicting 
anecdotal evidence that their inclusion may worsen symptoms and provoke attacks in some 
patients suffering with DD.  The results of the questionnaire distributed to SA dietitians indicated 
that the dietitians who participated in the study who were treating or who had treated DD, were 
not in agreement with the ICCG. 
 
Most dietitians recommended a high soluble fiber diet (86.6%) although 57.7% additionally 
prescribed a high insoluble fiber diet (wheat bran and bran flakes) with the exclusion of whole 
grains, skins, pips and nuts.  Under half (46.0%) promoted fiber supplementation, mainly soluble 
fiber (35.0%) which included oat bran, inulin, FOS, wheat dextrin and psyllium husks.  There 
was a significant reduction in abdominal symptoms noted in SUDD patients consuming 12g to 
24g of bran fiber as a supplement, although bran supplementation was not advised by dietitians.  
It was noted that a small percentage of patients did not benefit from bran supplementation and 
over half of the ICCG  do not promote their use in SUDD.  Despite not being in accordance with 
the ICCG, dietitians strongly believed that their approach improved patient symptoms and 
resulted in a reduced relapse rate. 
 
Approximately 80.0% identified trigger foods and the most popular were nuts, seeds, popcorn, 
pips, fruits, gas forming foods and fried/fatty foods.  There is limiting and conflicting evidence to 
support the use of a HFD and/or fiber supplementation in SUDD.  Anecdotal evidence from 
reputable websites and the dietitian’s beliefs regarding trigger foods were in opposition to the 





Although the majority believed that prebiotics were beneficial, only two prescribed them.  There 
was a general lack of knowledge regarding fiber supplements having a prebiotic effect, which 
may be partially attributed to the fact that available research on the use of prebiotics was poor. 
Many of the dietitians in the questionnaire prescribed probiotics.  A small minority recommended 
the actual probiotic strains found in VSL#3 and Vivomixx, that had been successfully researched 
and shown to reduce abdominal symptoms.  The others prescribed probiotic species and/or strains 
whose value in the treatment of SUDD had not been determined.  There was no direct evidence to 
support the use of omega-3 fish oil and glutamine supplements which a small minority of 
dietitians advised.  
  
The dietitians who participated in the study, believed that their approach improved patient’s 
symptoms and reduced the relapse rate in SUDD patients when they did not follow a liberal 
unrestricted high fiber approach in between acute attacks.  This appears to refute the conflicting 
ICCG which advocates a liberal unrestricted HFD.   Evidence indicates that there may be a sub-
section of SUDD sufferers that are intolerant to the high fiber approach and/or fiber supplements 
and who require an individualised approach to their dietary needs and required food restrictions.  
These individuals are often referred to dietitians for treatment only after the failure of the high 
fiber approach.  This would support the dietitian’s current perception that fiber restriction and 
reducing certain trigger foods may be necessary despite the ICCG.  Research on the use of 
prebiotics in SUDD has lacked focus and requires further investigation before promoting their 
use. The inclusion of probiotics is showing promise, though better quality controlled trials are 
needed to support the use in SUDD.   
 
6.2 CRITIQUE OF THE STUDY 
 
6.2.1 Study constraints/limitations 
  
• Registered dietitians who did not have access to the internet and email were not invited to 
participate in this study. 





• There was a lack of participation by RDs employed in the government sector as they 
required special permission by the Nutrition Directorate to complete the study.  
 
6.2.2 Recommendations for improvement of the study 
 
• To include a larger number of RDs in the study to help increase the sample size.   
• Registered dietitians in specilaised gastrointestinal units could be interviewed to 
determine their treatment methods.   
• Attend certain functions i.e.: ADSA workshops, where government and private practicing 
dietitians may attend and hand out questionnaires as well as collect them at the end of the 
function. 
• Investigating the current DD dietary practices that are taught by Universities to strengthen 
the results. 
 
6.3  RECOMMENDATIONS FOR NUTRITIONAL PRACTICE 
 
• An individualised assessment and approach is required for each SUDD patient in order to 
prescribe the best treatment method for that patient.   For some, the avoidance of certain 
insoluble fiber foods such as seeds, nuts, pips, popcorn, fruits, gas forming foods and 
fatty/fried foods may trigger an attack. These foods should be avoided initially and then 
introduced gradually to isolate the individual trigger foods. 
 
• Specific probiotics strains, such as Lactobacillus acidophilus 145, Lactobacillus casei 
subsp. DG, Lactobacillus helveticus ATC 15009, Lactobacillus paracasei B21060, 
Bifidobacterium spp. 420 and Escherichia coli Nissle 1917 and a probiotic mix (VSL#3, 
Vivomixx) may be supplemented. 
 
• Bran fiber supplements or soluble fiber supplements including oat bran, wheat dextrin, 
FOS and ispaghula/psyllium husk, were promoted by the dietitians and may be prescribed 
on an individual basis.   In the literature, a bran supplement of 12g-24g may reduce 





• Prebiotics such as FOS and inulin have not been extensively studied in SUDD and should 
not be prescribed until further studies prove their benefit in SUDD. 
 
• Omega-3 and glutamine are important for gut health, however, there are no studies to 
support their use in SUDD and should not be advised until further research supports their 
role in SUDD. 
 
6.4 IMPLICATIONS FOR FURTHER RESEARCH 
 
• The prevalence of DD in SA should be investigated.  
• To compare the efficacy of the two opposing approaches using a randomised trial. 
• To determine whether gastroenterologists believe that insoluble fiber affects the 
diverticula in DD. 
• To determine whether SUDD sufferers support the ICCG or whether they have identified 
trigger foods and which approach works best for them. 
• To determine the effectiveness of probiotics and prebiotics in SUDD. 
 
Further research is required to understand the prevalence of DD in SA and the best treatment 
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APPENDIX A: DIVERTICULAR QUESTIONNAIRE 
 
____________________________________________________ 
Please complete the mini questionnaire. The mini questionnaire is to establish the 
dietary treatment of diverticular disease.  
 
To ensure confidentiality your questionnaire responses will be allocated a study number 
and saved and your email correspondence deleted after that. Permission for this study 
has been given by the UKZN Humanities & Social Sciences Research Ethics Committee 
HSS/0179/012. The results of the survey will be released via the ADSA newsletter. 
______________________________________________________ 
1.  Do you currently treat or have you previously treated diverticular 
disease? Please underline the correct answer.  
1. Yes    
2. No  
 
 





2.  Where were you employed when you treated diverticular disease?  
You may select multiple options. Please underline the correct answer. 
• Government hospital 
• Private hospital 
• Private practice (self-employed) 
• Community service 
• University department 
• Clinical dietitian 
• Foodservice dietitian 
• Community dietitian 
• Clinic dietitian 
• Specialised Gastrointestinal unit 
 








3.  Have you found in your experience that there are foods that provoke 











4.  In your opinion are probiotics beneficial in the treatment of 
diverticular disease? Please underline the correct answer. 
1. Yes 
2. No 
3. Not sure 
 
_______________________________________________________ 
5.  In your opinion are prebiotics beneficial in the treatment of 





6.  Do you routinely prescribe any of the following supplements? Please 
underline the correct answer. 
1. Probiotics 
2. Prebiotics 




If you prescribe probiotics, please specify the product name and dose that you prescribe 
(if it differs from that recommended by the manufacturer) and briefly the reason for the 







If you prescribe prebiotics, please specify the product name and dose that you prescribe 
(if it differs from that recommended by the manufacturer) and briefly the reason for the 












7.  When your patients are in between acute attacks, which of the 
following approaches do you use? Please underline the correct 
answer 
1. A high mainly insoluble fiber diet (wheat bran, fruit skins, nuts, seeds, pips) with 
25 - 35g of fiber per day 
2. A high mainly insoluble fiber diet (wheat bran, fruit skins, nuts, seeds, pips) with 
31 - 45g of fiber per day 
3. A low insoluble fiber (avoid skins, nuts, seeds and pips) and high soluble fiber 
diet 
4. A high soluble fiber plus insoluble fiber (wheat bran, bran flakes) but with the 
avoidance of skins, pips, whole grains and nuts 
5. Other 




8.  Do you routinely prescribe a supplement of any of the following? 
Please underline the correct answer 
1. Insoluble fiber 
2. Soluble fiber 
3. Insoluble/soluble fiber blend 
4. Don't supplement fiber 
If you prescribe fiber supplements, please specify the product name and dose that you 
prescribe (if it differs from that recommended by the manufacturer) and briefly the 








9.  If you prescribe supplements other than pre/probiotics and fiber please 
specify the product name and dose that you prescribe (if it differs from that 










10.  Are there any further dietary modifications/restrictions that you 






11.  Do you find that your patients: 
1. Respond well with significant improvement in symptoms and have a decreased 
relapse rate? 
2. Respond well with significant improvement in symptoms and have a decreased 
relapse rate but that they feel that the diet is restrictive and impacts negatively on 
quality of life? 
3. Do not respond well and there are no significant improvement in symptoms and 
no decreased relapse rate? 
4. Other 






12. From your experience in treating diverticular patients, would you 
agree with the approach of not restricting insoluble fiber and/or allowing 
skins, pips, nuts and seeds with the use of high fiber supplements?  






13. The current guidelines for diverticular disease state that no changes 
in the diet are necessary and a patient can eat any fiber he/she wants. In 




If you disagreed, please specify which diet you would prescribe for a diverticular patient 









Thank you very much for completing this questionnaire. 
Your time and effort is highly appreciated. 
Please save your questionnaire 







School of Agricultural, Earth and Environmental Sciences 
iSikole seSayensi yeZolimo, eZomhlaba kanye Nemvelo 
Postal Address:  University of KwaZulu-Natal, Pietermaritzburg Campus, Private Bag X01, Scottsville, 3209 




















MASTERS STUDENT -DIVERTICULITIS SURVEY 
WIN a R1000 Gift Voucher from Yuppy Chef. 
If you are interested in your name being put into a draw for winning a R1000 Yuppy Chef Voucher, please 
complete the Diverticulitis Survey. If you have already completed the questionnaire,  your response has 
automatically been entered into the R1000 draw. 
The Diverticulitis Survey intends to establish whether practicing dietitians are implementing a high insoluble 
fiber diet or a low insoluble fiber diet (no nuts, skins, pips, seed) in the treatment of diverticular disease, 
whether supplements of fiber, prebiotics and probiotics are being prescribed and whether there are any 
particular foods that are thought to provoke attacks. The questionnaire takes less than 10 minutes to answer. If 
you do not treat diverticular disease, please send an email to tanyamarch@telkomsa.net and state that “you do 
not treat”, your response counts. 
Please follow this link, http://diveticulitis.weebly.com/ to enable you to complete the survey. The file will 
download into Word. The password is DIET. Please note that by sending the email you are providing informed 
consent. Please return the questionnaire to tanyamarch@telkomsa.net. The results will be forwarded to you 
once the masters has been completed. 
Chara Biggs (biggsc@ukzn.ac.za, 0814877950) is the supervisor for this masters. Permission for this study has 
been given by the UKZN Humanities & Social Sciences Research Ethics Committee HSS/0179/012.  If you 
have any questions, please contact Tanya March at tanyamarch@telkomsa.net or on her cell, 0845999021. 





Tanya March,RD (SA) 
Masters Student 
 
School of Agricultural, Earth and Environmental Sciences 
iSikole seSayensi yeZolimo, eZomhlaba kanye Nemvelo 
Postal Address:  University of KwaZulu-Natal, Pietermaritzburg Campus, Private Bag X01, Scottsville, 3209 
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